Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GDHG: 0.2500+0.0142 (+6.0221%)
Pre-Market: 0.4000 +0.1500 (+60.0000%)
Golden Heaven Group Holdings Ltd. (the "Company" or "Golden Heaven") (Nasdaq: GDHG), an amusement park operator in China, announced today that on February 21, 2024, the Company's Board of Directors (the "Board") has authorized a share repurchase program authorizing the Company to repurchase up to US$6,000,000 of the Company's outstanding Class A ordinary shares from time to time during a 24-month period (the "Share Repurchase Program"). The Share Repurchase Program will be facilitated by Dawson James Securities, Inc.
The Board has determined that the Share Repurchase Program is in the best interest of the Company's shareholders based on its analysis and estimation that the current share price is significantly lower than the intrinsic value and that the Share Repurchase Program may improve shareholders' confidence in the Company. The Board will be periodically reviewing the Share Repurchase Program and may authorize adjustments of its terms and size.
In determining the amount of capital to allocate to share repurchases, the Company takes into account, among other things, its historical and expected business performance, cash and liquidity position, as well as global economic and market conditions and the market price of the Company's Class A ordinary shares. The timing, manner, price, and amount of any repurchases under the Share Repurchase Program are determined by the Company in its discretion. Purchases may be affected through open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, or other means. The Company is not obligated to repurchase any specific number of Class A ordinary shares and the program may be modified, suspended, or discontinued at any time.
The Company intends to make all repurchases in compliance with applicable regulatory guidelines and to administer the plan in accordance with applicable laws.
About Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd. manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. With approximately 426,560 square meters of land in the aggregate, these parks are located in geographically diverse markets across the south of China and collectively offer approximately 139 rides and attractions. Due to the geographical locations of the parks and the ease of travel, the parks are easily accessible to an aggregate population of approximately 21 million people. Since September 30, 2023, Mangshi Jinsheng Amusement Park, which is one of the six parks, has been temporarily closed. The parks provide a wide range of exciting and entertaining experiences, including thrilling rides, family-friendly attractions, water attractions, gourmet festivals, circus performances, and high-tech facilities. For more information, please visit the Company's website at https://ir.jsyoule.com/.
ReShape Lifesciences Inc. (RSLS) : 0.1740+0.0076 (+4.5673%)
52 Week Range 0.1410 - 2.7600
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update
ReShape Lifesciences Inc
Wed, May 15, 2024, 10:05 PM
Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues
Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023
Implementation of 2024 Cost Reduction Plan Continues, Expected to Reduce Operating Expenses by 55.4% Compared to 2023
Conference Call to be Held at 4:30 pm ET Today
IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate strategic update.
First Quarter 2024 and Subsequent Highlights
March 2024: Significantly strengthened the company’s intellectual property portfolio related to an intragastric balloon system. Specifically, received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/370,819. The patent, number 11974934, was issued on May 7, 2024 and provides protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).
March 2024: Due to the continued impact on the company’s revenue caused by the rise in glucagon-like peptide 1 (GLP-1) receptor agonist prescriptions for weight loss, ReShape provided an update on its 2024 cost reduction plan, including a further Reduction in Force (RIF). Full implementation of the plan is expected to result in further lowering operating expenses of approximately $8.0 million in 2024, or more than a 50% reduction compared to 2023, excluding one-time costs.
February 2024: Announced that the first surgeries utilizing the company’s next generation, enhanced Lap-Band® 2.0 FLEX, were successfully performed by Adam Smith, D.O., Bariatric Surgery Specialist and Chief Executive Officer of Ultimate Bariatrics in Dallas, Fort Worth, TX, and Christine Ren-Fielding, M.D., Professor of Surgery at NYU Grossman School of Medicine, Director of NYU Langone Health’s Weight Management Program and Chief of the Division of Bariatric Surgery.
January 2024: Conducted bariatric fellows training for their Lap-Band® System, highlighting the Lap-Band® 2.0 FLEX.
“During the first quarter and subsequent period, we have remained focused on delivering shareholder value and are on a path to profitability, executing the 2024 cost reductions we outlined in March. To that end, we continue to fine-tune our lead generation activities and invest in our growth drivers, including the commercial launch of the Lap-Band® 2.0 FLEX,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences®. “With the adoption of GLP-1s, the stigma around obesity treatment is being replaced with medical intervention and we are steadfast in our confidence that the number of people seeking medical professionals, especially bariatric surgeons, will continue to increase. The first surgeries utilizing ReShape’s next generation, enhanced Lap-Band® 2.0 FLEX, designed to improve the patient experience, were successfully performed in February and additional surgeries have already taken place. Based on surgeon feedback, including those who have used the Lap-Band® 2.0 FLEX, we believe the market opportunity for the Lap-Band® franchise will increase, over time.
“In March, we significantly strengthened ReShape’s intellectual property portfolio surrounding the intragastric balloon system, having received a Notice of Allowance from the USPTO, and last week, had the patent issued. We will continue to build a defensive ‘moat’ around our product portfolio, innovation and commercialization efforts and, when necessary, we will take offensive action to defend our position utilizing non-dilutive funding. That said, as we continue through 2024, we are making significant progress implementing our 2024 cost reduction plan, which has included a further reduction in staff, expected to lower operating expenses by roughly 50%, compared to last year. These cuts are necessary to allow us to focus on our growth initiatives, by optimizing the commercialization of the Lap-Band® franchise. It is important to note that we are continuing our high priority search for synergistic M&A opportunities and, as previously reported, have engaged Maxim Group LLC, on an exclusive basis, to assist in this process. Finding the right partner will be key to the long-term success of ReShape Lifesciences. We look forward to providing further updates as the search continues.”
First Quarter Ended March 31, 2024, Financial and Operating Results
Revenue totaled $1.9 million for the three months ended March 31, 2024, which represents a contraction of 15.0%, or $0.3 million compared to the same period in 2023. The primary reason is due to a decrease in sales volume primarily due to GLP-1 pharmaceuticals.
Gross Profit for both three months ended March 31, 2023 and 2024, was $1.2 million. Gross profit as a percentage of total revenue for the three months ended March 31, 2024, was 59.9% compared to 53.5% for the same period in 2023. The increase in gross profit percentage is due to the reduction in overhead related costs, primarily payroll, as the Company had a reduction of employees late in 2023.
Sales and Marketing Expenses for the three months ended March 31, 2024, decreased by $1.2 million, or 53.3%, to $1.0 million, compared to $2.2 million for the same period in 2023. The decrease is primarily due to a decrease of $0.7 million in advertising and marketing expenses, including consulting and professional marketing services, as the Company has reevaluated its marketing approach and has moved to a targeted digital marketing campaign, resulting in a reduction of costs. The Company also had a reduction in payroll expenditure, including commissions, stock compensation expense and travel of $0.5 million, due to changes in sales personnel and lower sales.
General and Administrative Expenses for the three months ended March 31, 2024, decreased by $2.3 million, or 55.6%, to approximately $1.9 million, compared to $4.2 million for the same period in 2023. The decrease is primarily due to a reduction in professional services, such as audit and legal fees of $1.3 million primarily due to the fiscal year 2022 restatement that occurred during the first quarter of 2023, public stock offering costs, and a reduction in payroll-related expenses, including a reduction in stock-based compensation expense of $0.5 million, due to changes within personnel. The Company also had a decrease in rent and insurance of $0.1 million as it moved its headquarters during the second quarter of 2023 to a smaller facility to reduce costs.
Research and Development Expenses Research and development expenses were approximately $0.5 million for the three months ended March 31, 2024, remaining consistent with the same period in 2023, with a slight decrease primarily in stock based compensation.
Cash and Cash Equivalents As of March 31, 2024, the Company had net working capital of approximately $4.4 million, primarily due to cash and cash equivalents of $2.5 million, and $1.6 million of accounts receivable.
A full discussion of the company’s financials is available in our Annual Report on Form 10-Q, filed with the Securities and Exchange Commission.
Conference Call Information
Management will host a conference call to discuss ReShape’s financial and operational results today at 4:30 pm ET. To participate in the conference call please register with the following Registration Link, and dial-in details will be provided. Participants using this feature are requested to dial into the conference call fifteen minutes ahead of time to avoid delays.
An archived replay will also be available on the “Events and Presentations” section of ReShape’s website at: https://ir.reshapelifesciences.com/events-and-presentations.
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
ReShape Lifesciences Inc. (RSLS) : 0.1740+0.0076 (+4.5673%)
52 Week Range 0.1410 - 2.7600
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update
ReShape Lifesciences Inc
Wed, May 15, 2024, 10:05 PM
Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues
Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023
Implementation of 2024 Cost Reduction Plan Continues, Expected to Reduce Operating Expenses by 55.4% Compared to 2023
Conference Call to be Held at 4:30 pm ET Today
IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate strategic update.
First Quarter 2024 and Subsequent Highlights
March 2024: Significantly strengthened the company’s intellectual property portfolio related to an intragastric balloon system. Specifically, received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/370,819. The patent, number 11974934, was issued on May 7, 2024 and provides protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).
March 2024: Due to the continued impact on the company’s revenue caused by the rise in glucagon-like peptide 1 (GLP-1) receptor agonist prescriptions for weight loss, ReShape provided an update on its 2024 cost reduction plan, including a further Reduction in Force (RIF). Full implementation of the plan is expected to result in further lowering operating expenses of approximately $8.0 million in 2024, or more than a 50% reduction compared to 2023, excluding one-time costs.
February 2024: Announced that the first surgeries utilizing the company’s next generation, enhanced Lap-Band® 2.0 FLEX, were successfully performed by Adam Smith, D.O., Bariatric Surgery Specialist and Chief Executive Officer of Ultimate Bariatrics in Dallas, Fort Worth, TX, and Christine Ren-Fielding, M.D., Professor of Surgery at NYU Grossman School of Medicine, Director of NYU Langone Health’s Weight Management Program and Chief of the Division of Bariatric Surgery.
January 2024: Conducted bariatric fellows training for their Lap-Band® System, highlighting the Lap-Band® 2.0 FLEX.
“During the first quarter and subsequent period, we have remained focused on delivering shareholder value and are on a path to profitability, executing the 2024 cost reductions we outlined in March. To that end, we continue to fine-tune our lead generation activities and invest in our growth drivers, including the commercial launch of the Lap-Band® 2.0 FLEX,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences®. “With the adoption of GLP-1s, the stigma around obesity treatment is being replaced with medical intervention and we are steadfast in our confidence that the number of people seeking medical professionals, especially bariatric surgeons, will continue to increase. The first surgeries utilizing ReShape’s next generation, enhanced Lap-Band® 2.0 FLEX, designed to improve the patient experience, were successfully performed in February and additional surgeries have already taken place. Based on surgeon feedback, including those who have used the Lap-Band® 2.0 FLEX, we believe the market opportunity for the Lap-Band® franchise will increase, over time.
“In March, we significantly strengthened ReShape’s intellectual property portfolio surrounding the intragastric balloon system, having received a Notice of Allowance from the USPTO, and last week, had the patent issued. We will continue to build a defensive ‘moat’ around our product portfolio, innovation and commercialization efforts and, when necessary, we will take offensive action to defend our position utilizing non-dilutive funding. That said, as we continue through 2024, we are making significant progress implementing our 2024 cost reduction plan, which has included a further reduction in staff, expected to lower operating expenses by roughly 50%, compared to last year. These cuts are necessary to allow us to focus on our growth initiatives, by optimizing the commercialization of the Lap-Band® franchise. It is important to note that we are continuing our high priority search for synergistic M&A opportunities and, as previously reported, have engaged Maxim Group LLC, on an exclusive basis, to assist in this process. Finding the right partner will be key to the long-term success of ReShape Lifesciences. We look forward to providing further updates as the search continues.”
First Quarter Ended March 31, 2024, Financial and Operating Results
Revenue totaled $1.9 million for the three months ended March 31, 2024, which represents a contraction of 15.0%, or $0.3 million compared to the same period in 2023. The primary reason is due to a decrease in sales volume primarily due to GLP-1 pharmaceuticals.
Gross Profit for both three months ended March 31, 2023 and 2024, was $1.2 million. Gross profit as a percentage of total revenue for the three months ended March 31, 2024, was 59.9% compared to 53.5% for the same period in 2023. The increase in gross profit percentage is due to the reduction in overhead related costs, primarily payroll, as the Company had a reduction of employees late in 2023.
Sales and Marketing Expenses for the three months ended March 31, 2024, decreased by $1.2 million, or 53.3%, to $1.0 million, compared to $2.2 million for the same period in 2023. The decrease is primarily due to a decrease of $0.7 million in advertising and marketing expenses, including consulting and professional marketing services, as the Company has reevaluated its marketing approach and has moved to a targeted digital marketing campaign, resulting in a reduction of costs. The Company also had a reduction in payroll expenditure, including commissions, stock compensation expense and travel of $0.5 million, due to changes in sales personnel and lower sales.
General and Administrative Expenses for the three months ended March 31, 2024, decreased by $2.3 million, or 55.6%, to approximately $1.9 million, compared to $4.2 million for the same period in 2023. The decrease is primarily due to a reduction in professional services, such as audit and legal fees of $1.3 million primarily due to the fiscal year 2022 restatement that occurred during the first quarter of 2023, public stock offering costs, and a reduction in payroll-related expenses, including a reduction in stock-based compensation expense of $0.5 million, due to changes within personnel. The Company also had a decrease in rent and insurance of $0.1 million as it moved its headquarters during the second quarter of 2023 to a smaller facility to reduce costs.
Research and Development Expenses Research and development expenses were approximately $0.5 million for the three months ended March 31, 2024, remaining consistent with the same period in 2023, with a slight decrease primarily in stock based compensation.
Cash and Cash Equivalents As of March 31, 2024, the Company had net working capital of approximately $4.4 million, primarily due to cash and cash equivalents of $2.5 million, and $1.6 million of accounts receivable.
A full discussion of the company’s financials is available in our Annual Report on Form 10-Q, filed with the Securities and Exchange Commission.
Conference Call Information
Management will host a conference call to discuss ReShape’s financial and operational results today at 4:30 pm ET. To participate in the conference call please register with the following Registration Link, and dial-in details will be provided. Participants using this feature are requested to dial into the conference call fifteen minutes ahead of time to avoid delays.
An archived replay will also be available on the “Events and Presentations” section of ReShape’s website at: https://ir.reshapelifesciences.com/events-and-presentations.
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
Taoping TAOP : 0.75
Taoping Reports 25% YoY Increase in April Contract Revenue
PR Newswire
Wed, May 15, 2024, 2:30 PM
SHENZHEN, China, May 15, 2024 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), a developer of innovative smart cloud platform services and solutions, new media and artificial intelligence solutions, today reported a total contract revenue value of RMB 20.8 million (approximately USD $2.9 million) for the month of April 2024, representing an increase of 25% compared to the month of April 2023.
The Company highlighted that its impressive growth was driven by its commitment to innovation, as evident by the increased demand for its wide array of AI-based products, including its Smart City solutions.
Mr. Lin Jianghuai, Chairman and CEO of Taoping, said: "We are greatly encouraged by our ongoing expansion and the enthusiastic reception of our solutions portfolio from customers. Our focus on AI and cloud-based products has strategically aligned us with the solutions that customers find most compelling. These solutions, which are designed to enhance efficiency, improve end-customer interactions, and deliver a higher return on investment, have resonated well with the market."
"We have implemented multiple growth strategies that leverage AI to meet the dynamic needs of our customers. A key example is our recent introduction of Smart Terminals, which we believe will serve as a significant long-term growth driver for the Company. This initiative. is expected to play a pivotal role in enhancing shareholder value."
About Taoping Inc.
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us on X.
Taoping TAOP : 0.75
Taoping Reports 25% YoY Increase in April Contract Revenue
PR Newswire
Wed, May 15, 2024, 2:30 PM
SHENZHEN, China, May 15, 2024 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), a developer of innovative smart cloud platform services and solutions, new media and artificial intelligence solutions, today reported a total contract revenue value of RMB 20.8 million (approximately USD $2.9 million) for the month of April 2024, representing an increase of 25% compared to the month of April 2023.
The Company highlighted that its impressive growth was driven by its commitment to innovation, as evident by the increased demand for its wide array of AI-based products, including its Smart City solutions.
Mr. Lin Jianghuai, Chairman and CEO of Taoping, said: "We are greatly encouraged by our ongoing expansion and the enthusiastic reception of our solutions portfolio from customers. Our focus on AI and cloud-based products has strategically aligned us with the solutions that customers find most compelling. These solutions, which are designed to enhance efficiency, improve end-customer interactions, and deliver a higher return on investment, have resonated well with the market."
"We have implemented multiple growth strategies that leverage AI to meet the dynamic needs of our customers. A key example is our recent introduction of Smart Terminals, which we believe will serve as a significant long-term growth driver for the Company. This initiative. is expected to play a pivotal role in enhancing shareholder value."
About Taoping Inc.
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us on X.
Taoping Inc. (TAOP) : 0.7300-0.0801 (-9.89%)
Time for a strong rebound:
May 14, 2024 0.7305 0.7600 0.6800 0.7100 0.7100 312,456
May 13, 2024 0.8400 0.9200 0.8000 0.8100 0.8100 413,100
May 10, 2024 0.9000 0.9100 0.8200 0.8900 0.8900 788,600
May 09, 2024 1.1900 1.1900 0.8500 0.9800 0.9800 18,547,300
May 08, 2024 0.9400 0.9400 0.7800 0.8000 0.8000 246,000
May 07, 2024 0.9800 1.0100 0.9000 0.9200 0.9200 106,400
May 06, 2024 1.0100 1.0500 0.9500 1.0100 1.0100 36,500
May 03, 2024 1.0300 1.0500 1.0100 1.0200 1.0200 21,300
May 02, 2024 1.0700 1.0900 1.0000 1.0600 1.0600 96,300
May 01, 2024 1.0000 1.1000 0.9800 1.1000 1.1000 92,200
Apr 30, 2024 1.0000 1.0400 0.9200 1.0200 1.0200 146,200
Apr 29, 2024 1.0200 1.0300 0.9700 1.0000 1.0000 131,800
Apr 26, 2024 1.0000 1.0300 0.9800 0.9800 0.9800 159,000
Apr 25, 2024 1.0400 1.0800 0.9900 1.0400 1.0400 427,600
Apr 24, 2024 1.0900 1.1200 1.0300 1.0600 1.0600 99,70
SHENZHEN, China, May 9, 2024 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), a developer of innovative smart cloud platform services and solutions, new media and artificial intelligence solutions, today unveiled a new, upgraded AI-powered smart terminal. This cutting-edge platform integrates AI Generative Artificial Intelligence (AIGC) with Taoping's intelligent cloud platform technology and product capabilities, paving the way for intelligent, AI-driven smart terminals.
Taoping's new enhanced AI-powered smart terminals leverage high-end video displays to seamlessly integrate AI technology. This facilitates rapid interaction, data collection, analysis, and more, optimizing the user experience. Initially targeting advertisers, these enhanced terminals enable them to autonomously generate diverse advertising content such as text-to-image, posters, and video ads. This capability aligns with tailored promotional strategies, offering a high degree of customization. This capability allows the terminals to engage audiences naturally and instantly, significantly enhancing the efficacy of advertising media within Taoping's ecosystem.
Mr. Lin Jianghuai, Chairman and CEO of Taoping, commented, "It's evident that AI has emerged as a central focus for our customers seeking cutting-edge terminal solutions. Over the past year, we've deliberately architected our new AI-powered smart terminals to capitalize on the advanced capabilities of AI, seamlessly integrating them with our renowned intelligent cloud platform technology. The initial feedback from customers has been overwhelmingly positive. Our enhanced terminals not only promise to boost efficiency and cost-effectiveness for business owners, but they are also poised to elevate customer experiences. By delivering faster, more accurate service, they have the potential to reduce transaction costs significantly."
"This represents a significant milestone in Taoping's cloud strategy. While the initial application in advertising scenarios marks a promising start, we anticipate a much broader utilization of our new AI-powered smart terminals across various sectors including environmental protection, government affairs, retail, culture, and tourism. Our focus is firmly on leveraging these exciting opportunities to drive growth, supported comprehensively by the Company's expanded AI product series."
The integration of 3D simulated digital technology introduces groundbreaking interaction methods through AI technologies. Equipped with ultra-realistic dynamic service capabilities, advertisers from a variety of industries – including culture and tourism, catering, government affairs, finance, live streaming, and more – can now generate exclusive IP images that reflect with their unique characteristics.
At the same time, Taoping's new AI-powered smart terminals comprehensively optimize and upgrade multiple functions, such as intelligent auxiliary settings of advertising categories, scenarios, and specifications, as well as advertisements cloud storage and publishing. Covering every phase from content creation, precise publishing to marketing, and interaction with data analysis, Taoping's new AI-powered smart terminals will leverage AI to enhance each step of the process.
About Taoping Inc.
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us on X.
Taoping Inc. (TAOP) : 0.7300-0.0801 (-9.89%)
Time for a strong rebound:
May 14, 2024 0.7305 0.7600 0.6800 0.7100 0.7100 312,456
May 13, 2024 0.8400 0.9200 0.8000 0.8100 0.8100 413,100
May 10, 2024 0.9000 0.9100 0.8200 0.8900 0.8900 788,600
May 09, 2024 1.1900 1.1900 0.8500 0.9800 0.9800 18,547,300
May 08, 2024 0.9400 0.9400 0.7800 0.8000 0.8000 246,000
May 07, 2024 0.9800 1.0100 0.9000 0.9200 0.9200 106,400
May 06, 2024 1.0100 1.0500 0.9500 1.0100 1.0100 36,500
May 03, 2024 1.0300 1.0500 1.0100 1.0200 1.0200 21,300
May 02, 2024 1.0700 1.0900 1.0000 1.0600 1.0600 96,300
May 01, 2024 1.0000 1.1000 0.9800 1.1000 1.1000 92,200
Apr 30, 2024 1.0000 1.0400 0.9200 1.0200 1.0200 146,200
Apr 29, 2024 1.0200 1.0300 0.9700 1.0000 1.0000 131,800
Apr 26, 2024 1.0000 1.0300 0.9800 0.9800 0.9800 159,000
Apr 25, 2024 1.0400 1.0800 0.9900 1.0400 1.0400 427,600
Apr 24, 2024 1.0900 1.1200 1.0300 1.0600 1.0600 99,70
SHENZHEN, China, May 9, 2024 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), a developer of innovative smart cloud platform services and solutions, new media and artificial intelligence solutions, today unveiled a new, upgraded AI-powered smart terminal. This cutting-edge platform integrates AI Generative Artificial Intelligence (AIGC) with Taoping's intelligent cloud platform technology and product capabilities, paving the way for intelligent, AI-driven smart terminals.
Taoping's new enhanced AI-powered smart terminals leverage high-end video displays to seamlessly integrate AI technology. This facilitates rapid interaction, data collection, analysis, and more, optimizing the user experience. Initially targeting advertisers, these enhanced terminals enable them to autonomously generate diverse advertising content such as text-to-image, posters, and video ads. This capability aligns with tailored promotional strategies, offering a high degree of customization. This capability allows the terminals to engage audiences naturally and instantly, significantly enhancing the efficacy of advertising media within Taoping's ecosystem.
Mr. Lin Jianghuai, Chairman and CEO of Taoping, commented, "It's evident that AI has emerged as a central focus for our customers seeking cutting-edge terminal solutions. Over the past year, we've deliberately architected our new AI-powered smart terminals to capitalize on the advanced capabilities of AI, seamlessly integrating them with our renowned intelligent cloud platform technology. The initial feedback from customers has been overwhelmingly positive. Our enhanced terminals not only promise to boost efficiency and cost-effectiveness for business owners, but they are also poised to elevate customer experiences. By delivering faster, more accurate service, they have the potential to reduce transaction costs significantly."
"This represents a significant milestone in Taoping's cloud strategy. While the initial application in advertising scenarios marks a promising start, we anticipate a much broader utilization of our new AI-powered smart terminals across various sectors including environmental protection, government affairs, retail, culture, and tourism. Our focus is firmly on leveraging these exciting opportunities to drive growth, supported comprehensively by the Company's expanded AI product series."
The integration of 3D simulated digital technology introduces groundbreaking interaction methods through AI technologies. Equipped with ultra-realistic dynamic service capabilities, advertisers from a variety of industries – including culture and tourism, catering, government affairs, finance, live streaming, and more – can now generate exclusive IP images that reflect with their unique characteristics.
At the same time, Taoping's new AI-powered smart terminals comprehensively optimize and upgrade multiple functions, such as intelligent auxiliary settings of advertising categories, scenarios, and specifications, as well as advertisements cloud storage and publishing. Covering every phase from content creation, precise publishing to marketing, and interaction with data analysis, Taoping's new AI-powered smart terminals will leverage AI to enhance each step of the process.
About Taoping Inc.
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us on X.
ASTROTECH CORP (ASTC) : 9.90+0.24 (+2.64%)
52w: 7 – 15.11
Shares Outstanding 1.7M
Float 1.21M
Total Cash (mrq) 37.28M
Total Cash Per Share (mrq) 22.86
Total Debt (mrq) 461k
Book Value Per Share (mrq) 25.82
https://www.nasdaq.com/market-activity/stocks/astc/insider-activity
Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) announced that its Board of Directors (the “Board”) has unanimously rejected the unsolicited acquisition proposal from BML Investment Partners, L.P. (“BML”), to acquire all of the outstanding shares of common stock of the Company for $17.25 per share in cash (the “Proposal”). After a thorough review, in consultation with management and its legal advisors, the Board unanimously determined to reject the Proposal because it is not in the best interest of the Company’s stockholders for the reasons set forth below.
“We are confident that the completion of our key strategic projects has the potential to deliver greater value to our stockholders than the current non-binding proposal. Our board has reviewed the BML proposal and believes that it is grossly undervalued,” stated Thomas B. Pickens III, CEO and CTO of Astrotech.
The Proposal is Opportunistic and Significantly Undervalues the Company
• Astrotech’s consolidated balance sheet remains strong with $37 million in cash and liquid investments, which are anticipated to support our research and development, organic growth, and potential acquisition targets.
• Year-to-date fiscal year 2024 gross margin increased to 46% from 38% during the comparative period in the prior year, as we continue to benefit from the further refining and ruggedizing of our equipment.
Astrotech Corporation (NASDAQ: ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation (1st Detect), announce that 1st Detect’s TRACER 1000TM is now listed in the U.S. General Services Administration (GSA) IT Schedule 70 under Contract No. GS-35F-250GA with SRI Group LLC, Special Item Number 334290. IT Schedule 70 is a long-term contract issued by the GSA to commercial technology vendors that allows sales to the U. S. federal government, one of the largest buyers of goods and services in the world. GSA’s thorough evaluation determined that 1st Detect’s pricing is fair and reasonable, that 1st Detect had the requisite capabilities, organizational structure, customer satisfaction and performance history, and that the offered products and services are compliant with applicable laws and regulations.
1st Detect’s TRACER 1000 is a high-performance laboratory instrument of ruggedized mass spectrometry as applied to Explosives Trace Detection (ETD) and Narcotics Trace Detection (NTD). The TRACER 1000 maintains the accuracy of much larger mass spectrometers even though it is only the size of a desktop printer. While mass spectrometry has historically been too costly, bulky, and cumbersome to be used outside of the laboratory, the simple-to-use interface and auto-calibration process of the TRACER 1000 make it easy to use for rank-and-file checkpoint or other security personnel, at a fraction of the cost of traditional mass spectrometers.
The Astrotech Mass Spectrometer Technology™ drives the breakthrough TRACER 1000, as the first certified ETD to employ mass spectrometry. We believe the TRACER 1000 is inexpensive, small, and easy to use, with high resolution and near-zero false alarms. The TRACER 1000 is the only mass spectrometry-based ETD to have received European Civil Aviation Conference certification for both checkpoint and cargo security.
1st Detect has engaged with SRI Group LLC, a distinguished GSA provider led by retired Deputy Administrator of the Transportation Security Administration (TSA) John Halinski. He brings extensive knowledge and expertise in international aviation security, intelligence and counterterrorism. He is a member of the Board of Editors for the Government Technology Services Coalition’s magazine and media platform, Homeland Security Today, and is passionate about improving security and implementing the best practices and training procedures to achieve this. SRI Group LLC is a service disabled veteran owned small business, SDVOSB.
About Astrotech
Astrotech is an innovative science and technology company that invents, acquires, and commercializes technological innovations while building scalable companies to maximize shareholder value. 1st Detect develops, manufactures, and sells trace detectors for use in the security and detection market. Astrotech is headquartered in Austin, Texas. For more information, please visit www.astrotechcorp.com.
owned subsidiaries. 1st Detect develops, manufactures, and sells trace detectors for use in the security and detection market. AgLAB is developing chemical analyzers for use in the agriculture market. BreathTech is developing a breath analysis tool to provide early detection of lung diseases. Pro-Control is developing the mass spectrometry technology for use in chemical manufacturing processes. Astrotech is headquartered in Austin, Texas. For information, please visit www.astrotechcorp.com.
About the AgLAB-1000™, the BreathTest-1000™ and the Pro-Control-1000™
This press release contains information about our new products under development, AgLAB-1000, BreathTest-1000 and Pro-Control-1000. Product development involves a high degree of risk and uncertainty, and there can be no assurance that our new products will be successfully developed, achieve their intended benefits, receive full market authorization, or be commercially successful. In addition, FDA approval will be required to market BreathTest-1000 in the United States. Obtaining FDA approval is a complex and lengthy process, and there can be no assurance that FDA approval for BreathTest-1000 will be granted on a timely basis or at all.
Astrotech Corporation operates as a mass spectrometry company worldwide. It owns and licenses the intellectual property related to the Astrotech Mass Spectrometer Technology, a platform mass spectrometry technology. The company also develops TRACER 1000, a mass spectrometer-based explosive trace detector to replace the explosives trace detectors used at airports, cargo and other secured facilities, and borders. In addition, it develops AgLAB-1000, a mass spectrometer for use in the hemp and cannabis market. Further, the company develops BreathTest-1000, a breath analysis tool to screen for volatile organic compound metabolites found in a person's breath. The company was formerly known as SPACEHAB, Inc. and changed its name to Astrotech Corporation in 2009. The company was incorporated in 1984 and is based in Austin, Texas.
ASTROTECH CORP (ASTC) : 9.90+0.24 (+2.64%)
52w: 7 – 15.11
Shares Outstanding 1.7M
Float 1.21M
Total Cash (mrq) 37.28M
Total Cash Per Share (mrq) 22.86
Total Debt (mrq) 461k
Book Value Per Share (mrq) 25.82
https://www.nasdaq.com/market-activity/stocks/astc/insider-activity
Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) announced that its Board of Directors (the “Board”) has unanimously rejected the unsolicited acquisition proposal from BML Investment Partners, L.P. (“BML”), to acquire all of the outstanding shares of common stock of the Company for $17.25 per share in cash (the “Proposal”). After a thorough review, in consultation with management and its legal advisors, the Board unanimously determined to reject the Proposal because it is not in the best interest of the Company’s stockholders for the reasons set forth below.
“We are confident that the completion of our key strategic projects has the potential to deliver greater value to our stockholders than the current non-binding proposal. Our board has reviewed the BML proposal and believes that it is grossly undervalued,” stated Thomas B. Pickens III, CEO and CTO of Astrotech.
The Proposal is Opportunistic and Significantly Undervalues the Company
• Astrotech’s consolidated balance sheet remains strong with $37 million in cash and liquid investments, which are anticipated to support our research and development, organic growth, and potential acquisition targets.
• Year-to-date fiscal year 2024 gross margin increased to 46% from 38% during the comparative period in the prior year, as we continue to benefit from the further refining and ruggedizing of our equipment.
Astrotech Corporation (NASDAQ: ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation (1st Detect), announce that 1st Detect’s TRACER 1000TM is now listed in the U.S. General Services Administration (GSA) IT Schedule 70 under Contract No. GS-35F-250GA with SRI Group LLC, Special Item Number 334290. IT Schedule 70 is a long-term contract issued by the GSA to commercial technology vendors that allows sales to the U. S. federal government, one of the largest buyers of goods and services in the world. GSA’s thorough evaluation determined that 1st Detect’s pricing is fair and reasonable, that 1st Detect had the requisite capabilities, organizational structure, customer satisfaction and performance history, and that the offered products and services are compliant with applicable laws and regulations.
1st Detect’s TRACER 1000 is a high-performance laboratory instrument of ruggedized mass spectrometry as applied to Explosives Trace Detection (ETD) and Narcotics Trace Detection (NTD). The TRACER 1000 maintains the accuracy of much larger mass spectrometers even though it is only the size of a desktop printer. While mass spectrometry has historically been too costly, bulky, and cumbersome to be used outside of the laboratory, the simple-to-use interface and auto-calibration process of the TRACER 1000 make it easy to use for rank-and-file checkpoint or other security personnel, at a fraction of the cost of traditional mass spectrometers.
The Astrotech Mass Spectrometer Technology™ drives the breakthrough TRACER 1000, as the first certified ETD to employ mass spectrometry. We believe the TRACER 1000 is inexpensive, small, and easy to use, with high resolution and near-zero false alarms. The TRACER 1000 is the only mass spectrometry-based ETD to have received European Civil Aviation Conference certification for both checkpoint and cargo security.
1st Detect has engaged with SRI Group LLC, a distinguished GSA provider led by retired Deputy Administrator of the Transportation Security Administration (TSA) John Halinski. He brings extensive knowledge and expertise in international aviation security, intelligence and counterterrorism. He is a member of the Board of Editors for the Government Technology Services Coalition’s magazine and media platform, Homeland Security Today, and is passionate about improving security and implementing the best practices and training procedures to achieve this. SRI Group LLC is a service disabled veteran owned small business, SDVOSB.
About Astrotech
Astrotech is an innovative science and technology company that invents, acquires, and commercializes technological innovations while building scalable companies to maximize shareholder value. 1st Detect develops, manufactures, and sells trace detectors for use in the security and detection market. Astrotech is headquartered in Austin, Texas. For more information, please visit www.astrotechcorp.com.
owned subsidiaries. 1st Detect develops, manufactures, and sells trace detectors for use in the security and detection market. AgLAB is developing chemical analyzers for use in the agriculture market. BreathTech is developing a breath analysis tool to provide early detection of lung diseases. Pro-Control is developing the mass spectrometry technology for use in chemical manufacturing processes. Astrotech is headquartered in Austin, Texas. For information, please visit www.astrotechcorp.com.
About the AgLAB-1000™, the BreathTest-1000™ and the Pro-Control-1000™
This press release contains information about our new products under development, AgLAB-1000, BreathTest-1000 and Pro-Control-1000. Product development involves a high degree of risk and uncertainty, and there can be no assurance that our new products will be successfully developed, achieve their intended benefits, receive full market authorization, or be commercially successful. In addition, FDA approval will be required to market BreathTest-1000 in the United States. Obtaining FDA approval is a complex and lengthy process, and there can be no assurance that FDA approval for BreathTest-1000 will be granted on a timely basis or at all.
Astrotech Corporation operates as a mass spectrometry company worldwide. It owns and licenses the intellectual property related to the Astrotech Mass Spectrometer Technology, a platform mass spectrometry technology. The company also develops TRACER 1000, a mass spectrometer-based explosive trace detector to replace the explosives trace detectors used at airports, cargo and other secured facilities, and borders. In addition, it develops AgLAB-1000, a mass spectrometer for use in the hemp and cannabis market. Further, the company develops BreathTest-1000, a breath analysis tool to screen for volatile organic compound metabolites found in a person's breath. The company was formerly known as SPACEHAB, Inc. and changed its name to Astrotech Corporation in 2009. The company was incorporated in 1984 and is based in Austin, Texas.
ONVO: 1.17+0.2196 (+23.1103%)
Organovo Holdings (NASDAQ:ONVO) is a biotechnology company that is both a developer of 3D tissue technology that has the potential to change the way treatments are discovered and tested, as well as being a creator of new therapies using that technology.
The company recently released Phase 2 results for one of the therapies being advanced by ONVO by the name of FXR 314. The trial was to determine the effectiveness of FXR314 in treating metabolic function-associated steatohepatitis (MASH), which is a condition affecting approximately 115 million people worldwide according to the Boehringer Institute, which is expected to increase by roughly 25% by 2050. MASH, briefly, is a condition that can develop when excess fat is stored in the liver and causes inflammation of the liver, which can lead to a variety of problems, including liver failure. The serious nature of this condition is part of the reason we are excited about results from the Phase 2 trial, which showed a significant reduction in liver fat content for trial participants, with a mean reduction of 23% for those with 3 mg doses of FXR314, compared to a 6.1% reduction seen in those participants with a placebo.
Additionally, the company found that FXR 314 was found to be safe and effective. CEO Keith Murphy noted that, “The key findings of this study are that the once daily oral FXR314 demonstrated statistically significant liver fat reduction and excellent tolerability.”
These results reinforce our belief that ONVO is pursuing a path for developing drugs that is more effective and efficient and should prove to produce more impactful treatments.
As mentioned above, the company is a developer of 3D technology as well as a creator of new therapies. It is this dual path and how the two paths can work together that continues to excite us about Organovo. Regarding the 3D technology, Organovo’s advances in the area include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs across multiple therapeutic areas. The company’s technology, known as NovoGen Bioprinters, are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. The Company believes that the use of its bioprinting platform as well as complementary 3D technologies will allow it to develop an understanding of disease biology that leads to validated novel drug targets and therapeutics to those targets to treat disease. To this point, the company’s technology has been used to create a wide variety of tissues such as: healthy liver, NASH (nonalcoholic steatohepatitis) liver, kidney, intestine, skin, vascular, bone, skeletal muscle, eye, breast and pancreatic tumor.
There are two avenues that we believe the company can benefit from this technology. First, Organovo can use the technology internally to develop drugs that are able to be tailored more specifically to the targeted condition because the company can manipulate the 3D created tissues to reflect the disease as it would appear in actual human tissue. This also allows the company to move through the initial stages of research and testing in a more rapid and precise manner, which makes the process more efficient and cost effective and the treatments potentially more effective.
Additionally, many clinical stage companies have no revenue inflows to help offset the costs of developing much needed treatments. However, as already demonstrated, Organovo has the ability to license the company’s 3D technology to other companies to aid in their research process, leading to a revenue stream coming into Organovo as it continues to push to bring treatments to the market. According to company management, any deal achieved with a pharma company, Organovo intends to avoid “fee for services” revenue, which it believes provides limited benefit. Instead, the company will target deals with large, up-front payments, followed by milestone payments that the company believe could be in the hundreds of millions of dollars. These deals will involve the company working with the pharma partner to push novel drugs to the market. The partner company would own the rights to the drug, but Organovo would expect to earn milestone payments as a drug advances and royalties upon a drug’s commencement of commercial sales. These deals can be hard to predict the timing or probability of, but when achieved they have the potential to provide further validation of the company’s science and approach, as well as being a potential catalyst for investors.
We believe Organovo is at a good spot for potential investors, with positive test results providing confidence that the company is on the right track.
ONVO: 1.17+0.2196 (+23.1103%)
Organovo Holdings (NASDAQ:ONVO) is a biotechnology company that is both a developer of 3D tissue technology that has the potential to change the way treatments are discovered and tested, as well as being a creator of new therapies using that technology.
The company recently released Phase 2 results for one of the therapies being advanced by ONVO by the name of FXR 314. The trial was to determine the effectiveness of FXR314 in treating metabolic function-associated steatohepatitis (MASH), which is a condition affecting approximately 115 million people worldwide according to the Boehringer Institute, which is expected to increase by roughly 25% by 2050. MASH, briefly, is a condition that can develop when excess fat is stored in the liver and causes inflammation of the liver, which can lead to a variety of problems, including liver failure. The serious nature of this condition is part of the reason we are excited about results from the Phase 2 trial, which showed a significant reduction in liver fat content for trial participants, with a mean reduction of 23% for those with 3 mg doses of FXR314, compared to a 6.1% reduction seen in those participants with a placebo.
Additionally, the company found that FXR 314 was found to be safe and effective. CEO Keith Murphy noted that, “The key findings of this study are that the once daily oral FXR314 demonstrated statistically significant liver fat reduction and excellent tolerability.”
These results reinforce our belief that ONVO is pursuing a path for developing drugs that is more effective and efficient and should prove to produce more impactful treatments.
As mentioned above, the company is a developer of 3D technology as well as a creator of new therapies. It is this dual path and how the two paths can work together that continues to excite us about Organovo. Regarding the 3D technology, Organovo’s advances in the area include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs across multiple therapeutic areas. The company’s technology, known as NovoGen Bioprinters, are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. The Company believes that the use of its bioprinting platform as well as complementary 3D technologies will allow it to develop an understanding of disease biology that leads to validated novel drug targets and therapeutics to those targets to treat disease. To this point, the company’s technology has been used to create a wide variety of tissues such as: healthy liver, NASH (nonalcoholic steatohepatitis) liver, kidney, intestine, skin, vascular, bone, skeletal muscle, eye, breast and pancreatic tumor.
There are two avenues that we believe the company can benefit from this technology. First, Organovo can use the technology internally to develop drugs that are able to be tailored more specifically to the targeted condition because the company can manipulate the 3D created tissues to reflect the disease as it would appear in actual human tissue. This also allows the company to move through the initial stages of research and testing in a more rapid and precise manner, which makes the process more efficient and cost effective and the treatments potentially more effective.
Additionally, many clinical stage companies have no revenue inflows to help offset the costs of developing much needed treatments. However, as already demonstrated, Organovo has the ability to license the company’s 3D technology to other companies to aid in their research process, leading to a revenue stream coming into Organovo as it continues to push to bring treatments to the market. According to company management, any deal achieved with a pharma company, Organovo intends to avoid “fee for services” revenue, which it believes provides limited benefit. Instead, the company will target deals with large, up-front payments, followed by milestone payments that the company believe could be in the hundreds of millions of dollars. These deals will involve the company working with the pharma partner to push novel drugs to the market. The partner company would own the rights to the drug, but Organovo would expect to earn milestone payments as a drug advances and royalties upon a drug’s commencement of commercial sales. These deals can be hard to predict the timing or probability of, but when achieved they have the potential to provide further validation of the company’s science and approach, as well as being a potential catalyst for investors.
We believe Organovo is at a good spot for potential investors, with positive test results providing confidence that the company is on the right track.
fuboTV Inc. (FUBO) : 1.55
52 Week Range 1.2020 - 3.8700
FUBOTV SHARES RISE 16% PREMARKET AFTER CO REPORTS SMALLER-THAN-EXPECTED Q1 LOSS, REVENUE BEATS EST
Fubo Exceeded Q1 2024 Guidance in North America, Delivering 1.511M Paid Subscribers, $394M Total Revenue
Guidance
Given the many unknowns related to the potential launch of the JV, including the outcome of the antitrust lawsuit and reported Department of Justice investigation, the Company’s guidance and planned path to profitability do not reflect any potential impact of the JV launch to its business.
North America
Second Quarter 2024: Fubo is projecting 1,275,000 to 1,295,000 subscribers, representing 10% YoY growth at the midpoint, and $357.5 to $367.5 million total revenue, representing 19% YoY growth at the midpoint.
Full Year 2024: Fubo is projecting 1,675,000 to 1,695,000 subscribers, representing 4% YoY growth at the midpoint, and $1.525 to $1.545 billion total revenue, representing 15% YoY growth at the midpoint.
Fubo’s projection of revenue growth outpacing subscriber growth reflects the Company’s expectation of continued ARPU expansion and improved unit economics. Subscriber growth reflects conservatism in the Company’s outlook and, in particular, exposure to potential industry volatility, as well as Fubo’s intention to maintain discipline in subscriber acquisition costs relative to monetization, but does not reflect any potential impact of the JV launch.
ROW
Second Quarter 2024: Fubo is projecting 395,000 to 400,000 subscribers, representing 1% YoY at the midpoint, and $8 to $9 million total revenue, representing 4% YoY growth at the midpoint.
Full Year 2024: Fubo is projecting 395,000 to 405,000 subscribers, representing a -2% YoY decline at the midpoint, and $33 to $35 million total revenue, representing 4% YoY growth at the midpoint.
Complete first quarter 2024 results are detailed in Fubo’s shareholder letter available on the company’s IR site.
"Fubo’s first quarter 2024 performance builds upon the strong momentum achieved in the prior year, with double digit paid subscribers, total revenue and ad revenue growth in North America," said David Gandler, co-founder and CEO, Fubo. "Our results further underscore continued solid execution on our long-term strategy. We continue to operate efficiently and effectively as we execute on our mission to delight consumers with an aggregated sports entertainment offering delivered through a personalized and intuitive streaming experience."
Gandler continued: "We continue to believe in the merits of our antitrust lawsuit against the sports streaming JV partners and thank those who have publicly supported us. We are encouraged by reports of the Department of Justice’s investigation and look forward to our preliminary injunction hearing in August. Fubo believes if all distributors were offered fair terms, the consumer could have multiple and robust sports streaming options to choose from, access to just the channels they want, and at a price that's right for them."
"As we look ahead, the Fubo team remains focused on the core business as well as making progress against our strategic priorities," said Edgar Bronfman Jr., executive chairman, Fubo. "We are balancing our profitability targets and growth while advancing in our technology capabilities, features and content. Over the past seven quarters, Fubo has consistently met or exceeded guidance and expanded ARPU in a challenging macro environment, all the while delivering a world-class viewing experience for consumers. We remain confident in our ability to build on this success while aggressively working to establish a more fair and equitable playing field for Fubo, other media industry participants and above all, consumers."
fuboTV Inc. (FUBO) : 1.55
52 Week Range 1.2020 - 3.8700
FUBOTV SHARES RISE 16% PREMARKET AFTER CO REPORTS SMALLER-THAN-EXPECTED Q1 LOSS, REVENUE BEATS EST
Fubo Exceeded Q1 2024 Guidance in North America, Delivering 1.511M Paid Subscribers, $394M Total Revenue
Guidance
Given the many unknowns related to the potential launch of the JV, including the outcome of the antitrust lawsuit and reported Department of Justice investigation, the Company’s guidance and planned path to profitability do not reflect any potential impact of the JV launch to its business.
North America
Second Quarter 2024: Fubo is projecting 1,275,000 to 1,295,000 subscribers, representing 10% YoY growth at the midpoint, and $357.5 to $367.5 million total revenue, representing 19% YoY growth at the midpoint.
Full Year 2024: Fubo is projecting 1,675,000 to 1,695,000 subscribers, representing 4% YoY growth at the midpoint, and $1.525 to $1.545 billion total revenue, representing 15% YoY growth at the midpoint.
Fubo’s projection of revenue growth outpacing subscriber growth reflects the Company’s expectation of continued ARPU expansion and improved unit economics. Subscriber growth reflects conservatism in the Company’s outlook and, in particular, exposure to potential industry volatility, as well as Fubo’s intention to maintain discipline in subscriber acquisition costs relative to monetization, but does not reflect any potential impact of the JV launch.
ROW
Second Quarter 2024: Fubo is projecting 395,000 to 400,000 subscribers, representing 1% YoY at the midpoint, and $8 to $9 million total revenue, representing 4% YoY growth at the midpoint.
Full Year 2024: Fubo is projecting 395,000 to 405,000 subscribers, representing a -2% YoY decline at the midpoint, and $33 to $35 million total revenue, representing 4% YoY growth at the midpoint.
Complete first quarter 2024 results are detailed in Fubo’s shareholder letter available on the company’s IR site.
"Fubo’s first quarter 2024 performance builds upon the strong momentum achieved in the prior year, with double digit paid subscribers, total revenue and ad revenue growth in North America," said David Gandler, co-founder and CEO, Fubo. "Our results further underscore continued solid execution on our long-term strategy. We continue to operate efficiently and effectively as we execute on our mission to delight consumers with an aggregated sports entertainment offering delivered through a personalized and intuitive streaming experience."
Gandler continued: "We continue to believe in the merits of our antitrust lawsuit against the sports streaming JV partners and thank those who have publicly supported us. We are encouraged by reports of the Department of Justice’s investigation and look forward to our preliminary injunction hearing in August. Fubo believes if all distributors were offered fair terms, the consumer could have multiple and robust sports streaming options to choose from, access to just the channels they want, and at a price that's right for them."
"As we look ahead, the Fubo team remains focused on the core business as well as making progress against our strategic priorities," said Edgar Bronfman Jr., executive chairman, Fubo. "We are balancing our profitability targets and growth while advancing in our technology capabilities, features and content. Over the past seven quarters, Fubo has consistently met or exceeded guidance and expanded ARPU in a challenging macro environment, all the while delivering a world-class viewing experience for consumers. We remain confident in our ability to build on this success while aggressively working to establish a more fair and equitable playing field for Fubo, other media industry participants and above all, consumers."
Organovo Holdings, Inc. (ONVO) : 0.9701-0.0999 (-9.34%)
Shares Outstanding 11.39M
Float 9.87M
https://www.otcmarkets.com/filing/conv_pdf?id=17496946&guid=LJQ-kapzYH7fJth
May 01, 2024 0.9800 1.0200 0.9700 0.9701 0.9701 235,655
Apr 30, 2024 1.0500 1.0900 1.0300 1.0700 1.0700 69,200
Apr 29, 2024 0.9900 1.0600 0.9900 1.0400 1.0400 111,800
Apr 26, 2024 0.9900 1.0300 0.9800 1.0000 1.0000 139,300
Apr 25, 2024 0.9800 1.0200 0.9800 0.9900 0.9900 72,900
Apr 24, 2024 0.9900 1.0300 0.9900 1.0000 1.0000 117,000
Apr 23, 2024 1.0000 1.0600 1.0000 1.0000 1.0000 127,100
Apr 22, 2024 1.0700 1.1200 1.0100 1.0300 1.0300 297,900
Apr 19, 2024 1.1500 1.1900 1.1000 1.1000 1.1000 275,200
Apr 18, 2024 1.1000 1.2900 1.0900 1.1500 1.1500 579,000
Apr 17, 2024 1.1100 1.2100 1.0500 1.1200 1.1200 550,900
Apr 16, 2024 1.2800 1.3000 1.1000 1.1500 1.1500 1,941,500
Apr 15, 2024 1.6600 1.7400 1.2000 1.3500 1.3500 53,785,500
Apr 12, 2024 1.0200 1.0400 1.0000 1.0100 1.0100 52,700
Organovo Holdings (NASDAQ:ONVO) is a biotechnology company that is both a developer of 3D tissue technology that has the potential to change the way treatments are discovered and tested, as well as being a creator of new therapies using that technology.
The company recently released Phase 2 results for one of the therapies being advanced by ONVO by the name of FXR 314. The trial was to determine the effectiveness of FXR314 in treating metabolic function-associated steatohepatitis (MASH), which is a condition affecting approximately 115 million people worldwide according to the Boehringer Institute, which is expected to increase by roughly 25% by 2050. MASH, briefly, is a condition that can develop when excess fat is stored in the liver and causes inflammation of the liver, which can lead to a variety of problems, including liver failure. The serious nature of this condition is part of the reason we are excited about results from the Phase 2 trial, which showed a significant reduction in liver fat content for trial participants, with a mean reduction of 23% for those with 3 mg doses of FXR314, compared to a 6.1% reduction seen in those participants with a placebo.
Additionally, the company found that FXR 314 was found to be safe and effective. CEO Keith Murphy noted that, “The key findings of this study are that the once daily oral FXR314 demonstrated statistically significant liver fat reduction and excellent tolerability.”
These results reinforce our belief that ONVO is pursuing a path for developing drugs that is more effective and efficient and should prove to produce more impactful treatments.
As mentioned above, the company is a developer of 3D technology as well as a creator of new therapies. It is this dual path and how the two paths can work together that continues to excite us about Organovo. Regarding the 3D technology, Organovo’s advances in the area include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs across multiple therapeutic areas. The company’s technology, known as NovoGen Bioprinters, are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. The Company believes that the use of its bioprinting platform as well as complementary 3D technologies will allow it to develop an understanding of disease biology that leads to validated novel drug targets and therapeutics to those targets to treat disease. To this point, the company’s technology has been used to create a wide variety of tissues such as: healthy liver, NASH (nonalcoholic steatohepatitis) liver, kidney, intestine, skin, vascular, bone, skeletal muscle, eye, breast and pancreatic tumor.
There are two avenues that we believe the company can benefit from this technology. First, Organovo can use the technology internally to develop drugs that are able to be tailored more specifically to the targeted condition because the company can manipulate the 3D created tissues to reflect the disease as it would appear in actual human tissue. This also allows the company to move through the initial stages of research and testing in a more rapid and precise manner, which makes the process more efficient and cost effective and the treatments potentially more effective.
Additionally, many clinical stage companies have no revenue inflows to help offset the costs of developing much needed treatments. However, as already demonstrated, Organovo has the ability to license the company’s 3D technology to other companies to aid in their research process, leading to a revenue stream coming into Organovo as it continues to push to bring treatments to the market. According to company management, any deal achieved with a pharma company, Organovo intends to avoid “fee for services” revenue, which it believes provides limited benefit. Instead, the company will target deals with large, up-front payments, followed by milestone payments that the company believe could be in the hundreds of millions of dollars. These deals will involve the company working with the pharma partner to push novel drugs to the market. The partner company would own the rights to the drug, but Organovo would expect to earn milestone payments as a drug advances and royalties upon a drug’s commencement of commercial sales. These deals can be hard to predict the timing or probability of, but when achieved they have the potential to provide further validation of the company’s science and approach, as well as being a potential catalyst for investors.
We believe Organovo is at a good spot for potential investors, with positive test results providing confidence that the company is on the right track.
Apr 01, 2024 1.0300 1.7400 0.9800 1.0700 1.0700 58,338,700
Mar 01, 2024 1.0200 1.2400 0.9800 1.0300 1.0300 2,902,500
Feb 01, 2024 1.0400 1.1700 0.8900 1.0200 1.0200 2,468,800
Jan 01, 2024 1.1000 1.2700 1.0000 1.0200 1.0200 2,263,200
Dec 01, 2023 1.1500 1.3900 1.0500 1.1100 1.1100 6,634,400
Nov 01, 2023 1.1000 2.0500 1.1000 1.1700 1.1700 5,603,100
Oct 01, 2023 1.2100 1.4300 1.0500 1.0600 1.0600 479,500
Sep 01, 2023 1.2000 1.6400 1.0000 1.2500 1.2500 1,245,100
Aug 01, 2023 1.6500 1.6700 1.1400 1.2000 1.2000 685,800
Jul 01, 2023 1.6200 1.9600 1.6200 1.6700 1.6700 535,400
Jun 01, 2023 1.7100 1.9500 1.6100 1.6900 1.6900 478,300
May 01, 2023 1.9500 2.0300 1.7000 1.7000 1.7000 440,700
Apr 01, 2023 2.2000 2.2500 1.7500 1.9500 1.9500 476,600
Mar 01, 2023 2.3200 2.3700 1.7400 2.1900 2.1900 1,132,600
Feb 01, 2023 1.6000 3.4000 1.6000 2.3700 2.3700 5,776,700
Jan 01, 2023 1.4700 1.8900 1.4000 1.6300 1.6300 638,700
Dec 01, 2022 1.5200 1.9000 1.3700 1.4100 1.4100 470,700
Nov 01, 2022 1.7000 1.7100 1.4500 1.5100 1.5100 392,100
Oct 01, 2022 2.1000 2.2300 1.6000 1.6400 1.6400 523,400
Sep 01, 2022 2.6200 2.8600 1.8700 2.0500 2.0500 3,562,200
Aug 01, 2022 2.9000 3.7200 2.2800 2.3600 2.3600 1,104,600
Jul 01, 2022 1.8800 3.6300 1.7500 2.9400 2.9400 4,779,500
Jun 01, 2022 2.3900 2.5400 1.7100 1.7700 1.7700 652,500
May 01, 2022 2.9200 2.9400 2.2400 2.4100 2.4100 439,900
Apr 01, 2022 3.7200 3.7900 2.8400 2.8700 2.8700 450,800
Mar 01, 2022 3.7300 4.6700 3.3400 3.7600 3.7600 1,061,400
Feb 01, 2022 3.1600 3.6400 2.6500 3.5600 3.5600 834,600
Jan 01, 2022 3.7300 4.4800 2.5600 3.1200 3.1200 1,288,000
Dec 01, 2021 4.8600 5.2000 3.6300 3.6300 3.6300 1,480,200
Nov 01, 2021 6.1800 6.5900 4.4100 4.7900 4.7900 1,478,300
Oct 01, 2021 6.7800 6.9700 5.8800 6.2100 6.2100 1,031,100
Sep 01, 2021 7.7100 8.1300 6.5000 6.8000 6.8000 950,200
Aug 01, 2021 7.5800 8.3000 6.0500 7.6600 7.6600 1,757,000
Jul 01, 2021 9.4700 9.5600 7.2600 7.6700 7.6700 1,186,900
Jun 01, 2021 9.3700 9.8900 7.7100 9.4000 9.4000 4,603,200
May 01, 2021 8.5600 11.2500 6.5000 9.4000 9.4000 9,836,900
Apr 01, 2021 10.0300 10.4200 7.5300 8.5400 8.5400 2,893,200
Mar 01, 2021 13.3300 14.0900 8.2400 9.6400 9.6400 5,366,500
Feb 01, 2021 12.7500 23.9200 11.0300 12.7500 12.7500 10,810,700
Jan 01, 2021 12.4600 17.4000 10.6300 12.7900 12.7900 6,828,400
Dec 01, 2020 8.5500 20.4900 7.0300 12.3000 12.3000 7,949,400
Nov 01, 2020 8.9800 10.6800 8.4100 8.5500 8.5500 1,889,700
Oct 01, 2020 7.9000 11.6600 6.8600 8.5800 8.5800 3,889,700
Sep 01, 2020 9.1800 9.8900 6.0200 7.9100 7.9100 2,242,700
Aug 01, 2020 13.0000 15.6000 7.1900 9.1200 9.1200 2,053,350
Jul 01, 2020 11.2000 17.4000 11.2000 13.2000 13.2000 1,603,005
Jun 01, 2020 13.2000 15.6000 9.4000 11.0000 11.0000 1,163,685
May 01, 2020 8.4000 18.6000 7.8000 12.6000 12.6000 2,742,405
Apr 01, 2020 7.4000 9.0000 4.8000 8.4000 8.4000 822,850
Mar 01, 2020 6.2000 9.0000 3.8000 8.2000 8.2000 869,975
Feb 01, 2020 6.4000 7.2000 5.2000 6.4000 6.4000 412,345
Jan 01, 2020 7.4000 10.2000 6.2000 6.4000 6.4000 713,350
Dec 01, 2019 10.4000 13.0000 7.0000 7.2000 7.2000 776,335
Nov 01, 2019 6.2000 10.4000 6.2000 10.0000 10.0000 822,955
Oct 01, 2019 5.2000 6.8000 5.0000 6.0000 6.0000 628,355
Sep 01, 2019 5.0000 6.4000 4.8000 5.2000 5.2000 388,390
Aug 01, 2019 8.2000 8.8000 4.4000 5.2000 5.2000 1,077,395
Jul 01, 2019 10.6000 11.0000 8.2000 8.2000 8.2000 763,825
Jun 01, 2019 12.2000 12.2000 8.0000 10.4000 10.4000 2,801,700
May 01, 2019 19.8000 21.0000 7.4000 11.0000 11.0000 4,216,855
Apr 01, 2019 20.6000 21.0000 19.2000 20.0000 20.0000 569,565
Mar 01, 2019 21.2000 23.2000 19.2000 19.8000 19.8000 875,270
Feb 01, 2019 20.2000 23.6000 19.0000 21.2000 21.2000 593,370
Jan 01, 2019 18.6000 23.2000 18.2000 20.2000 20.2000 585,970
Dec 01, 2018 19.8000 21.2000 18.0000 19.2000 19.2000 535,770
Nov 01, 2018 20.4000 25.4000 18.0000 19.4000 19.4000 513,085
Oct 01, 2018 22.8000 23.8000 19.8000 20.2000 20.2000 548,380
Sep 01, 2018 26.0000 26.2000 22.4000 23.0000 23.0000 504,515
Aug 01, 2018 23.8000 27.6000 21.0000 25.8000 25.8000 717,665
Jul 01, 2018 27.4000 28.8000 21.6000 23.8000 23.8000 656,945
Jun 01, 2018 36.6000 38.4000 25.2000 28.0000 28.0000 1,331,290
May 01, 2018 25.0000 41.8000 23.0000 39.4000 39.4000 1,589,720
Apr 01, 2018 20.6000 26.4000 18.2000 24.8000 24.8000 1,031,170
Mar 01, 2018 20.2000 24.8000 19.4000 20.6000 20.6000 723,335
Feb 01, 2018 27.8000 30.8000 18.6000 20.2000 20.2000 1,151,910
Jan 01, 2018 27.0000 30.0000 26.4000 28.0000 28.0000 1,155,930
Dec 01, 2017 30.0000 34.0000 26.4000 26.8000 26.8000 1,773,095
Nov 01, 2017 32.8000 34.6000 26.6000 30.2000 30.2000 956,150
Oct 01, 2017 44.4000 45.6000 26.4000 31.8000 31.8000 2,016,175
Sep 01, 2017 41.6000 47.6000 39.0000 44.4000 44.4000 923,775
Aug 01, 2017 47.2000 47.2000 35.0000 41.6000 41.6000 1,005,585
Jul 01, 2017 52.6000 54.4000 45.8000 46.8000 46.8000 641,220
Jun 01, 2017 56.6000 60.6000 51.0000 52.6000 52.6000 943,360
May 01, 2017 58.6000 63.8000 52.8000 56.6000 56.6000 1,008,445
Apr 01, 2017 63.4000 63.8000 51.6000 58.0000 58.0000 848,715
Mar 01, 2017 63.0000 65.2000 55.2000 63.6000 63.6000 1,138,240
Feb 01, 2017 74.6000 77.0000 56.8000 62.4000 62.4000 1,655,225
Jan 01, 2017 70.8000 78.4000 67.0000 73.8000 73.8000 1,266,630
Dec 01, 2016 60.2000 81.6000 57.2000 67.8000 67.8000 1,932,080
Nov 01, 2016 52.6000 68.0000 50.0000 60.4000 60.4000 1,133,225
Oct 01, 2016 76.0000 82.8000 49.6000 49.8000 49.8000 1,453,975
Sep 01, 2016 76.8000 85.6000 73.8000 75.8000 75.8000 757,900
Aug 01, 2016 88.0000 99.8000 74.6000 77.2000 77.2000 1,330,340
Jul 01, 2016 74.8000 88.0000 73.6000 85.6000 85.6000 1,310,520
Jun 01, 2016 58.0000 74.8000 55.4000 74.4000 74.4000 979,690
May 01, 2016 54.4000 61.0000 48.2000 58.4000 58.4000 427,830
Apr 01, 2016 43.4000 59.6000 42.2000 54.4000 54.4000 704,230
Mar 01, 2016 46.0000 52.8000 40.0000 43.4000 43.4000 777,025
Feb 01, 2016 39.4000 48.8000 34.8000 45.0000 45.0000 705,540
Jan 01, 2016 48.8000 51.2000 32.0000 39.2000 39.2000 878,200
Dec 01, 2015 68.0000 69.6000 49.8000 49.8000 49.8000 807,620
Nov 01, 2015 60.0000 69.4000 57.4000 67.8000 67.8000 709,990
Oct 01, 2015 53.8000 69.0000 47.4000 60.2000 60.2000 1,159,270
Sep 01, 2015 53.0000 81.6000 48.4000 53.6000 53.6000 1,624,565
Aug 01, 2015 67.0000 73.0000 38.0000 54.6000 54.6000 1,803,630
Jul 01, 2015 76.6000 82.6000 65.2000 67.6000 67.6000 1,557,020
Jun 01, 2015 100.2000 116.4000 72.8000 75.4000 75.4000 2,259,105
May 01, 2015 90.2000 103.4000 88.4000 100.2000 100.2000 847,660
Apr 01, 2015 79.8000 109.0000 70.0000 90.8000 90.8000 3,083,420
Mar 01, 2015 118.8000 122.4000 65.8000 70.8000 70.8000 1,918,625
Feb 01, 2015 127.0000 131.4000 116.2000 118.4000 118.4000 813,940
Jan 01, 2015 143.2000 148.4000 120.2000 128.6000 128.6000 715,755
Dec 01, 2014 127.2000 153.6000 107.0000 145.0000 145.0000 1,635,865
Nov 01, 2014 130.2000 148.0000 122.8000 126.2000 126.2000 854,790
Oct 01, 2014 127.4000 133.6000 107.8000 130.8000 130.8000 1,098,555
Sep 01, 2014 157.0000 157.0000 123.4000 127.4000 127.4000 941,075
Aug 01, 2014 150.2000 167.0000 142.0000 155.6000 155.6000 973,065
Jul 01, 2014 168.8000 185.0000 137.0000 151.4000 151.4000 1,644,960
Jun 01, 2014 143.0000 182.0000 125.2000 167.0000 167.0000 1,806,020
May 01, 2014 118.4000 148.4000 115.0000 142.4000 142.4000 1,044,495
Apr 01, 2014 155.8000 173.6000 102.4000 116.8000 116.8000 2,098,785
Mar 01, 2014 200.4000 209.0000 142.4000 152.8000 152.8000 2,017,390
Feb 01, 2014 188.0000 216.8000 170.0000 205.6000 205.6000 2,105,485
Jan 01, 2014 226.0000 247.6000 163.4000 189.0000 189.0000 5,330,400
Dec 01, 2013 175.0000 230.8000 162.0000 221.4000 221.4000 3,619,930
Nov 01, 2013 150.0000 273.0000 132.2000 177.6000 177.6000 10,327,500
Organovo Holdings, Inc. (ONVO) : 0.9701-0.0999 (-9.34%)
Shares Outstanding 11.39M
Float 9.87M
https://www.otcmarkets.com/filing/conv_pdf?id=17496946&guid=LJQ-kapzYH7fJth
May 01, 2024 0.9800 1.0200 0.9700 0.9701 0.9701 235,655
Apr 30, 2024 1.0500 1.0900 1.0300 1.0700 1.0700 69,200
Apr 29, 2024 0.9900 1.0600 0.9900 1.0400 1.0400 111,800
Apr 26, 2024 0.9900 1.0300 0.9800 1.0000 1.0000 139,300
Apr 25, 2024 0.9800 1.0200 0.9800 0.9900 0.9900 72,900
Apr 24, 2024 0.9900 1.0300 0.9900 1.0000 1.0000 117,000
Apr 23, 2024 1.0000 1.0600 1.0000 1.0000 1.0000 127,100
Apr 22, 2024 1.0700 1.1200 1.0100 1.0300 1.0300 297,900
Apr 19, 2024 1.1500 1.1900 1.1000 1.1000 1.1000 275,200
Apr 18, 2024 1.1000 1.2900 1.0900 1.1500 1.1500 579,000
Apr 17, 2024 1.1100 1.2100 1.0500 1.1200 1.1200 550,900
Apr 16, 2024 1.2800 1.3000 1.1000 1.1500 1.1500 1,941,500
Apr 15, 2024 1.6600 1.7400 1.2000 1.3500 1.3500 53,785,500
Apr 12, 2024 1.0200 1.0400 1.0000 1.0100 1.0100 52,700
Organovo Holdings (NASDAQ:ONVO) is a biotechnology company that is both a developer of 3D tissue technology that has the potential to change the way treatments are discovered and tested, as well as being a creator of new therapies using that technology.
The company recently released Phase 2 results for one of the therapies being advanced by ONVO by the name of FXR 314. The trial was to determine the effectiveness of FXR314 in treating metabolic function-associated steatohepatitis (MASH), which is a condition affecting approximately 115 million people worldwide according to the Boehringer Institute, which is expected to increase by roughly 25% by 2050. MASH, briefly, is a condition that can develop when excess fat is stored in the liver and causes inflammation of the liver, which can lead to a variety of problems, including liver failure. The serious nature of this condition is part of the reason we are excited about results from the Phase 2 trial, which showed a significant reduction in liver fat content for trial participants, with a mean reduction of 23% for those with 3 mg doses of FXR314, compared to a 6.1% reduction seen in those participants with a placebo.
Additionally, the company found that FXR 314 was found to be safe and effective. CEO Keith Murphy noted that, “The key findings of this study are that the once daily oral FXR314 demonstrated statistically significant liver fat reduction and excellent tolerability.”
These results reinforce our belief that ONVO is pursuing a path for developing drugs that is more effective and efficient and should prove to produce more impactful treatments.
As mentioned above, the company is a developer of 3D technology as well as a creator of new therapies. It is this dual path and how the two paths can work together that continues to excite us about Organovo. Regarding the 3D technology, Organovo’s advances in the area include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs across multiple therapeutic areas. The company’s technology, known as NovoGen Bioprinters, are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. The Company believes that the use of its bioprinting platform as well as complementary 3D technologies will allow it to develop an understanding of disease biology that leads to validated novel drug targets and therapeutics to those targets to treat disease. To this point, the company’s technology has been used to create a wide variety of tissues such as: healthy liver, NASH (nonalcoholic steatohepatitis) liver, kidney, intestine, skin, vascular, bone, skeletal muscle, eye, breast and pancreatic tumor.
There are two avenues that we believe the company can benefit from this technology. First, Organovo can use the technology internally to develop drugs that are able to be tailored more specifically to the targeted condition because the company can manipulate the 3D created tissues to reflect the disease as it would appear in actual human tissue. This also allows the company to move through the initial stages of research and testing in a more rapid and precise manner, which makes the process more efficient and cost effective and the treatments potentially more effective.
Additionally, many clinical stage companies have no revenue inflows to help offset the costs of developing much needed treatments. However, as already demonstrated, Organovo has the ability to license the company’s 3D technology to other companies to aid in their research process, leading to a revenue stream coming into Organovo as it continues to push to bring treatments to the market. According to company management, any deal achieved with a pharma company, Organovo intends to avoid “fee for services” revenue, which it believes provides limited benefit. Instead, the company will target deals with large, up-front payments, followed by milestone payments that the company believe could be in the hundreds of millions of dollars. These deals will involve the company working with the pharma partner to push novel drugs to the market. The partner company would own the rights to the drug, but Organovo would expect to earn milestone payments as a drug advances and royalties upon a drug’s commencement of commercial sales. These deals can be hard to predict the timing or probability of, but when achieved they have the potential to provide further validation of the company’s science and approach, as well as being a potential catalyst for investors.
We believe Organovo is at a good spot for potential investors, with positive test results providing confidence that the company is on the right track.
Apr 01, 2024 1.0300 1.7400 0.9800 1.0700 1.0700 58,338,700
Mar 01, 2024 1.0200 1.2400 0.9800 1.0300 1.0300 2,902,500
Feb 01, 2024 1.0400 1.1700 0.8900 1.0200 1.0200 2,468,800
Jan 01, 2024 1.1000 1.2700 1.0000 1.0200 1.0200 2,263,200
Dec 01, 2023 1.1500 1.3900 1.0500 1.1100 1.1100 6,634,400
Nov 01, 2023 1.1000 2.0500 1.1000 1.1700 1.1700 5,603,100
Oct 01, 2023 1.2100 1.4300 1.0500 1.0600 1.0600 479,500
Sep 01, 2023 1.2000 1.6400 1.0000 1.2500 1.2500 1,245,100
Aug 01, 2023 1.6500 1.6700 1.1400 1.2000 1.2000 685,800
Jul 01, 2023 1.6200 1.9600 1.6200 1.6700 1.6700 535,400
Jun 01, 2023 1.7100 1.9500 1.6100 1.6900 1.6900 478,300
May 01, 2023 1.9500 2.0300 1.7000 1.7000 1.7000 440,700
Apr 01, 2023 2.2000 2.2500 1.7500 1.9500 1.9500 476,600
Mar 01, 2023 2.3200 2.3700 1.7400 2.1900 2.1900 1,132,600
Feb 01, 2023 1.6000 3.4000 1.6000 2.3700 2.3700 5,776,700
Jan 01, 2023 1.4700 1.8900 1.4000 1.6300 1.6300 638,700
Dec 01, 2022 1.5200 1.9000 1.3700 1.4100 1.4100 470,700
Nov 01, 2022 1.7000 1.7100 1.4500 1.5100 1.5100 392,100
Oct 01, 2022 2.1000 2.2300 1.6000 1.6400 1.6400 523,400
Sep 01, 2022 2.6200 2.8600 1.8700 2.0500 2.0500 3,562,200
Aug 01, 2022 2.9000 3.7200 2.2800 2.3600 2.3600 1,104,600
Jul 01, 2022 1.8800 3.6300 1.7500 2.9400 2.9400 4,779,500
Jun 01, 2022 2.3900 2.5400 1.7100 1.7700 1.7700 652,500
May 01, 2022 2.9200 2.9400 2.2400 2.4100 2.4100 439,900
Apr 01, 2022 3.7200 3.7900 2.8400 2.8700 2.8700 450,800
Mar 01, 2022 3.7300 4.6700 3.3400 3.7600 3.7600 1,061,400
Feb 01, 2022 3.1600 3.6400 2.6500 3.5600 3.5600 834,600
Jan 01, 2022 3.7300 4.4800 2.5600 3.1200 3.1200 1,288,000
Dec 01, 2021 4.8600 5.2000 3.6300 3.6300 3.6300 1,480,200
Nov 01, 2021 6.1800 6.5900 4.4100 4.7900 4.7900 1,478,300
Oct 01, 2021 6.7800 6.9700 5.8800 6.2100 6.2100 1,031,100
Sep 01, 2021 7.7100 8.1300 6.5000 6.8000 6.8000 950,200
Aug 01, 2021 7.5800 8.3000 6.0500 7.6600 7.6600 1,757,000
Jul 01, 2021 9.4700 9.5600 7.2600 7.6700 7.6700 1,186,900
Jun 01, 2021 9.3700 9.8900 7.7100 9.4000 9.4000 4,603,200
May 01, 2021 8.5600 11.2500 6.5000 9.4000 9.4000 9,836,900
Apr 01, 2021 10.0300 10.4200 7.5300 8.5400 8.5400 2,893,200
Mar 01, 2021 13.3300 14.0900 8.2400 9.6400 9.6400 5,366,500
Feb 01, 2021 12.7500 23.9200 11.0300 12.7500 12.7500 10,810,700
Jan 01, 2021 12.4600 17.4000 10.6300 12.7900 12.7900 6,828,400
Dec 01, 2020 8.5500 20.4900 7.0300 12.3000 12.3000 7,949,400
Nov 01, 2020 8.9800 10.6800 8.4100 8.5500 8.5500 1,889,700
Oct 01, 2020 7.9000 11.6600 6.8600 8.5800 8.5800 3,889,700
Sep 01, 2020 9.1800 9.8900 6.0200 7.9100 7.9100 2,242,700
Aug 01, 2020 13.0000 15.6000 7.1900 9.1200 9.1200 2,053,350
Jul 01, 2020 11.2000 17.4000 11.2000 13.2000 13.2000 1,603,005
Jun 01, 2020 13.2000 15.6000 9.4000 11.0000 11.0000 1,163,685
May 01, 2020 8.4000 18.6000 7.8000 12.6000 12.6000 2,742,405
Apr 01, 2020 7.4000 9.0000 4.8000 8.4000 8.4000 822,850
Mar 01, 2020 6.2000 9.0000 3.8000 8.2000 8.2000 869,975
Feb 01, 2020 6.4000 7.2000 5.2000 6.4000 6.4000 412,345
Jan 01, 2020 7.4000 10.2000 6.2000 6.4000 6.4000 713,350
Dec 01, 2019 10.4000 13.0000 7.0000 7.2000 7.2000 776,335
Nov 01, 2019 6.2000 10.4000 6.2000 10.0000 10.0000 822,955
Oct 01, 2019 5.2000 6.8000 5.0000 6.0000 6.0000 628,355
Sep 01, 2019 5.0000 6.4000 4.8000 5.2000 5.2000 388,390
Aug 01, 2019 8.2000 8.8000 4.4000 5.2000 5.2000 1,077,395
Jul 01, 2019 10.6000 11.0000 8.2000 8.2000 8.2000 763,825
Jun 01, 2019 12.2000 12.2000 8.0000 10.4000 10.4000 2,801,700
May 01, 2019 19.8000 21.0000 7.4000 11.0000 11.0000 4,216,855
Apr 01, 2019 20.6000 21.0000 19.2000 20.0000 20.0000 569,565
Mar 01, 2019 21.2000 23.2000 19.2000 19.8000 19.8000 875,270
Feb 01, 2019 20.2000 23.6000 19.0000 21.2000 21.2000 593,370
Jan 01, 2019 18.6000 23.2000 18.2000 20.2000 20.2000 585,970
Dec 01, 2018 19.8000 21.2000 18.0000 19.2000 19.2000 535,770
Nov 01, 2018 20.4000 25.4000 18.0000 19.4000 19.4000 513,085
Oct 01, 2018 22.8000 23.8000 19.8000 20.2000 20.2000 548,380
Sep 01, 2018 26.0000 26.2000 22.4000 23.0000 23.0000 504,515
Aug 01, 2018 23.8000 27.6000 21.0000 25.8000 25.8000 717,665
Jul 01, 2018 27.4000 28.8000 21.6000 23.8000 23.8000 656,945
Jun 01, 2018 36.6000 38.4000 25.2000 28.0000 28.0000 1,331,290
May 01, 2018 25.0000 41.8000 23.0000 39.4000 39.4000 1,589,720
Apr 01, 2018 20.6000 26.4000 18.2000 24.8000 24.8000 1,031,170
Mar 01, 2018 20.2000 24.8000 19.4000 20.6000 20.6000 723,335
Feb 01, 2018 27.8000 30.8000 18.6000 20.2000 20.2000 1,151,910
Jan 01, 2018 27.0000 30.0000 26.4000 28.0000 28.0000 1,155,930
Dec 01, 2017 30.0000 34.0000 26.4000 26.8000 26.8000 1,773,095
Nov 01, 2017 32.8000 34.6000 26.6000 30.2000 30.2000 956,150
Oct 01, 2017 44.4000 45.6000 26.4000 31.8000 31.8000 2,016,175
Sep 01, 2017 41.6000 47.6000 39.0000 44.4000 44.4000 923,775
Aug 01, 2017 47.2000 47.2000 35.0000 41.6000 41.6000 1,005,585
Jul 01, 2017 52.6000 54.4000 45.8000 46.8000 46.8000 641,220
Jun 01, 2017 56.6000 60.6000 51.0000 52.6000 52.6000 943,360
May 01, 2017 58.6000 63.8000 52.8000 56.6000 56.6000 1,008,445
Apr 01, 2017 63.4000 63.8000 51.6000 58.0000 58.0000 848,715
Mar 01, 2017 63.0000 65.2000 55.2000 63.6000 63.6000 1,138,240
Feb 01, 2017 74.6000 77.0000 56.8000 62.4000 62.4000 1,655,225
Jan 01, 2017 70.8000 78.4000 67.0000 73.8000 73.8000 1,266,630
Dec 01, 2016 60.2000 81.6000 57.2000 67.8000 67.8000 1,932,080
Nov 01, 2016 52.6000 68.0000 50.0000 60.4000 60.4000 1,133,225
Oct 01, 2016 76.0000 82.8000 49.6000 49.8000 49.8000 1,453,975
Sep 01, 2016 76.8000 85.6000 73.8000 75.8000 75.8000 757,900
Aug 01, 2016 88.0000 99.8000 74.6000 77.2000 77.2000 1,330,340
Jul 01, 2016 74.8000 88.0000 73.6000 85.6000 85.6000 1,310,520
Jun 01, 2016 58.0000 74.8000 55.4000 74.4000 74.4000 979,690
May 01, 2016 54.4000 61.0000 48.2000 58.4000 58.4000 427,830
Apr 01, 2016 43.4000 59.6000 42.2000 54.4000 54.4000 704,230
Mar 01, 2016 46.0000 52.8000 40.0000 43.4000 43.4000 777,025
Feb 01, 2016 39.4000 48.8000 34.8000 45.0000 45.0000 705,540
Jan 01, 2016 48.8000 51.2000 32.0000 39.2000 39.2000 878,200
Dec 01, 2015 68.0000 69.6000 49.8000 49.8000 49.8000 807,620
Nov 01, 2015 60.0000 69.4000 57.4000 67.8000 67.8000 709,990
Oct 01, 2015 53.8000 69.0000 47.4000 60.2000 60.2000 1,159,270
Sep 01, 2015 53.0000 81.6000 48.4000 53.6000 53.6000 1,624,565
Aug 01, 2015 67.0000 73.0000 38.0000 54.6000 54.6000 1,803,630
Jul 01, 2015 76.6000 82.6000 65.2000 67.6000 67.6000 1,557,020
Jun 01, 2015 100.2000 116.4000 72.8000 75.4000 75.4000 2,259,105
May 01, 2015 90.2000 103.4000 88.4000 100.2000 100.2000 847,660
Apr 01, 2015 79.8000 109.0000 70.0000 90.8000 90.8000 3,083,420
Mar 01, 2015 118.8000 122.4000 65.8000 70.8000 70.8000 1,918,625
Feb 01, 2015 127.0000 131.4000 116.2000 118.4000 118.4000 813,940
Jan 01, 2015 143.2000 148.4000 120.2000 128.6000 128.6000 715,755
Dec 01, 2014 127.2000 153.6000 107.0000 145.0000 145.0000 1,635,865
Nov 01, 2014 130.2000 148.0000 122.8000 126.2000 126.2000 854,790
Oct 01, 2014 127.4000 133.6000 107.8000 130.8000 130.8000 1,098,555
Sep 01, 2014 157.0000 157.0000 123.4000 127.4000 127.4000 941,075
Aug 01, 2014 150.2000 167.0000 142.0000 155.6000 155.6000 973,065
Jul 01, 2014 168.8000 185.0000 137.0000 151.4000 151.4000 1,644,960
Jun 01, 2014 143.0000 182.0000 125.2000 167.0000 167.0000 1,806,020
May 01, 2014 118.4000 148.4000 115.0000 142.4000 142.4000 1,044,495
Apr 01, 2014 155.8000 173.6000 102.4000 116.8000 116.8000 2,098,785
Mar 01, 2014 200.4000 209.0000 142.4000 152.8000 152.8000 2,017,390
Feb 01, 2014 188.0000 216.8000 170.0000 205.6000 205.6000 2,105,485
Jan 01, 2014 226.0000 247.6000 163.4000 189.0000 189.0000 5,330,400
Dec 01, 2013 175.0000 230.8000 162.0000 221.4000 221.4000 3,619,930
Nov 01, 2013 150.0000 273.0000 132.2000 177.6000 177.6000 10,327,500
GDHG : Premarket: $0.417 + 20.04%
I hope we see at least 0.45 today = 98% below a few months ago and before a 6 Million buyback.
Golden Heaven Group Holdings Ltd. (the "Company" or "Golden Heaven") (Nasdaq: GDHG), an amusement park operator in China, announced today that on February 21, 2024, the Company's Board of Directors (the "Board") has authorized a share repurchase program authorizing the Company to repurchase up to US$6,000,000 of the Company's outstanding Class A ordinary shares from time to time during a 24-month period (the "Share Repurchase Program"). The Share Repurchase Program will be facilitated by Dawson James Securities, Inc.
The Board has determined that the Share Repurchase Program is in the best interest of the Company's shareholders based on its analysis and estimation that the current share price is significantly lower than the intrinsic value and that the Share Repurchase Program may improve shareholders' confidence in the Company. The Board will be periodically reviewing the Share Repurchase Program and may authorize adjustments of its terms and size.
In determining the amount of capital to allocate to share repurchases, the Company takes into account, among other things, its historical and expected business performance, cash and liquidity position, as well as global economic and market conditions and the market price of the Company's Class A ordinary shares. The timing, manner, price, and amount of any repurchases under the Share Repurchase Program are determined by the Company in its discretion. Purchases may be affected through open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, or other means. The Company is not obligated to repurchase any specific number of Class A ordinary shares and the program may be modified, suspended, or discontinued at any time.
The Company intends to make all repurchases in compliance with applicable regulatory guidelines and to administer the plan in accordance with applicable laws.
About Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd. manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. With approximately 426,560 square meters of land in the aggregate, these parks are located in geographically diverse markets across the south of China and collectively offer approximately 139 rides and attractions. Due to the geographical locations of the parks and the ease of travel, the parks are easily accessible to an aggregate population of approximately 21 million people. Since September 30, 2023, Mangshi Jinsheng Amusement Park, which is one of the six parks, has been temporarily closed. The parks provide a wide range of exciting and entertaining experiences, including thrilling rides, family-friendly attractions, water attractions, gourmet festivals, circus performances, and high-tech facilities. For more information, please visit the Company's website at https://ir.jsyoule.com/.
GDHG : Premarket: $0.417 + 20.04%
I hope we see at least 0.45 today = 98% below a few months ago and before a 6 Million buyback.
Golden Heaven Group Holdings Ltd. (the "Company" or "Golden Heaven") (Nasdaq: GDHG), an amusement park operator in China, announced today that on February 21, 2024, the Company's Board of Directors (the "Board") has authorized a share repurchase program authorizing the Company to repurchase up to US$6,000,000 of the Company's outstanding Class A ordinary shares from time to time during a 24-month period (the "Share Repurchase Program"). The Share Repurchase Program will be facilitated by Dawson James Securities, Inc.
The Board has determined that the Share Repurchase Program is in the best interest of the Company's shareholders based on its analysis and estimation that the current share price is significantly lower than the intrinsic value and that the Share Repurchase Program may improve shareholders' confidence in the Company. The Board will be periodically reviewing the Share Repurchase Program and may authorize adjustments of its terms and size.
In determining the amount of capital to allocate to share repurchases, the Company takes into account, among other things, its historical and expected business performance, cash and liquidity position, as well as global economic and market conditions and the market price of the Company's Class A ordinary shares. The timing, manner, price, and amount of any repurchases under the Share Repurchase Program are determined by the Company in its discretion. Purchases may be affected through open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, or other means. The Company is not obligated to repurchase any specific number of Class A ordinary shares and the program may be modified, suspended, or discontinued at any time.
The Company intends to make all repurchases in compliance with applicable regulatory guidelines and to administer the plan in accordance with applicable laws.
About Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd. manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. With approximately 426,560 square meters of land in the aggregate, these parks are located in geographically diverse markets across the south of China and collectively offer approximately 139 rides and attractions. Due to the geographical locations of the parks and the ease of travel, the parks are easily accessible to an aggregate population of approximately 21 million people. Since September 30, 2023, Mangshi Jinsheng Amusement Park, which is one of the six parks, has been temporarily closed. The parks provide a wide range of exciting and entertaining experiences, including thrilling rides, family-friendly attractions, water attractions, gourmet festivals, circus performances, and high-tech facilities. For more information, please visit the Company's website at https://ir.jsyoule.com/.
Float down to: Float 1.74M
https://finance.yahoo.com/quote/GDHG/key-statistics
source: Yahoo finance
Time for a strong rebound
GDHG: 0.36 + 0.0841 (+30.48%)
very low flow: https://finance.yahoo.com/quote/GDHG/key-statistics (Float :1.74M)
https://twitter.com/GoldenHeavenLTD/status/1785321051422871979/photo/1
https://twitter.com/GoldenHeavenLTD/status/1785009005074509987/photo/1
Time for a strong rebound
GDHG: 0.36 + 0.0841 (+30.48%)
very low flow: https://finance.yahoo.com/quote/GDHG/key-statistics (Float :1.74M)
https://twitter.com/GoldenHeavenLTD/status/1785321051422871979/photo/1
https://twitter.com/GoldenHeavenLTD/status/1785009005074509987/photo/1
RCON: 0.0910 + 10.97%
Day’s range: 0.085 – 0.1397
Stock was up more than 70% intraday, I hope for a repeat on Monday!
RCON: 0.0910 + 10.97%
Day’s range: 0.085 – 0.1397
Stock was up more than 70% intraday, I hope for a repeat on Monday!
0,2968 +15,08%
I hope 0.35 by Friday
And here we go again: GDHG : 0.3090+0.0503 (+19.4434%)
very low free float:
Shares Outstanding 41.75M
Float 2.16M
And here we go again: GDHG : 0.3090+0.0503 (+19.4434%)
very low free float:
Shares Outstanding 41.75M
Float 2.16M
GDHG: 0.2488 + 0.0215 (9.46%)
A lot of visitors : https://twitter.com/frontpagestocks/status/1782848948538921073/photo/1
GDHG: 0.2488 + 0.0215 (9.46%)
A lot of visitors : https://twitter.com/frontpagestocks/status/1782848948538921073/photo/1
Yahoo mb:
float got reduced from 11.2 mil to 2.16 mil today, according to yahoo, the buy back is happening. I hope it’ll squeeze with more buy backs later on
Short interest is at 40% now, the buy back is definitely happening
Shares Outstanding 41.75M
Implied Shares Outstanding 51.75M
Float 2.16M
Golden Heaven Group Holdings Ltd. (GDHG) : 0.2389 + 5.11%
52 Week Range 0.2030 - 24.9900
I think we will go up very much when the news is spread:
Yahoo mb:
I tripled my position today, averaged out at 0.251 the float got reduced from 11.2 mil to 2.16 mil today, according to yahoo, the buy back is happening. I hope it’ll squeeze with more buy backs later on
Short interest is at 40% now, the buy back is definitely happening
Shares Outstanding 41.75M
Implied Shares Outstanding 51.75M
Float 2.16M
Golden Heaven Group Holdings Ltd. (GDHG) : 0.2389 + 5.11%
52 Week Range 0.2030 - 24.9900
I think we will go up very much when the news is spread:
Yahoo mb:
I tripled my position today, averaged out at 0.251 the float got reduced from 11.2 mil to 2.16 mil today, according to yahoo, the buy back is happening. I hope it’ll squeeze with more buy backs later on
Short interest is at 40% now, the buy back is definitely happening
Shares Outstanding 41.75M
Implied Shares Outstanding 51.75M
Float 2.16M
Great news.
GDHG: 0.2402
The ex-ceo sold her shares for 0.30 to an investment fund.
JINZHENG INVESTMENT CO PTE. LTD. (“JINZHENG”), a Singapore company that had held 5,000,000 class A ordinary shares and
10,000,000 Class B ordinary shares of Golden Heaven Group Holdings Ltd. (the “Company”) and is 100% owned by Qiong Jin, entered into a share purchase
agreement (the “Agreement”) with YITONG ASIA INVESTMENT PTE. LTD. (“YITONG”), an exempt private company limited by shares incorporated in
Singapore that is 100% owned by Cuizhang Gong, pursuant to which JINZHENG has agreed to sell to YITONG, and YITONG has agreed to purchase from
JINZHENG, all of JINZHENG’s right, title and interest in and pertaining to 10,000,000 Class B ordinary shares of the Company (the “Shares”) at a purchase price of $0.30 per share.
so no sales pressure
When they start the buyback off 6 million we can go up very fast.
Golden Heaven Group Holdings Ltd. Announces $6,000,000 Share Repurchase Program.
Float: 19.7M
Short: 9.2 %
Thursday afterhours we went to 0.438
Great news.
GDHG: 0.2402
The ex-ceo sold her shares for 0.30 to an investment fund.
JINZHENG INVESTMENT CO PTE. LTD. (“JINZHENG”), a Singapore company that had held 5,000,000 class A ordinary shares and
10,000,000 Class B ordinary shares of Golden Heaven Group Holdings Ltd. (the “Company”) and is 100% owned by Qiong Jin, entered into a share purchase
agreement (the “Agreement”) with YITONG ASIA INVESTMENT PTE. LTD. (“YITONG”), an exempt private company limited by shares incorporated in
Singapore that is 100% owned by Cuizhang Gong, pursuant to which JINZHENG has agreed to sell to YITONG, and YITONG has agreed to purchase from
JINZHENG, all of JINZHENG’s right, title and interest in and pertaining to 10,000,000 Class B ordinary shares of the Company (the “Shares”) at a purchase price of $0.30 per share.
so no sales pressure
When they start the buyback off 6 million we can go up very fast.
Golden Heaven Group Holdings Ltd. Announces $6,000,000 Share Repurchase Program.
Float: 19.7M
Short: 9.2 %
Thursday afterhours we went to 0.438
GDHG: After hours: 0.43 + 0.167 (+63,51%)
https://ir.jsyoule.com/companyinformation.html?type=company
Like I said, back to $1, down 99%, time for shorters to cover, first they cover and then the company can start buying back.
Golden Heaven Group Holdings Ltd. Announces $6,000,000 Share Repurchase Program.
Float: 19.7M
Short: 9.2 %
$GDHG - Our amusement parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals and theatrical shows.https://t.co/zTVx94FDB6 @Nasdaq #China #AmusementParks $DIS $SEAS $SIX pic.twitter.com/HrE2W6EMHm
— Golden Heaven Group Holdings Ltd. (@GoldenHeavenLTD) April 17, 2024
GDHG: After hours: 0.43 + 0.167 (+63,51%)
https://ir.jsyoule.com/companyinformation.html?type=company
Like I said, back to $1, down 99%, time for shorters to cover, first they cover and then the company can start buying back.
Golden Heaven Group Holdings Ltd. Announces $6,000,000 Share Repurchase Program.
Float: 19.7M
Short: 9.2 %
$GDHG - Our amusement parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals and theatrical shows.https://t.co/zTVx94FDB6 @Nasdaq #China #AmusementParks $DIS $SEAS $SIX pic.twitter.com/HrE2W6EMHm
— Golden Heaven Group Holdings Ltd. (@GoldenHeavenLTD) April 17, 2024
Time for a strong rebound:
WNBD: 0.0003 + 500%
Volume: more than 250.000.000
https://twitter.com/WinningCEO
Winning Brands Corporation is a Canada-based company. The Company is providing products in two categories: chemical and electronic technology. The chemical division, Niagara Mist Marketing, focuses on cleaning agents with an environmental focus. Its product portfolio includes 1000+ stain remover, BRILLIANT Professional Laundry Solutions, TrackMoist, and ReGUARD4. 1000+ Stain Remover is a solution that spans a range of clean-up situations from home improvement messes to degreasing and stain removal of all sorts from both hard surfaces (floors, walls, decks) and soft surfaces (carpets and fabric). BRILLIANT Professional Laundry Solutions is a commercial garment cleaning and finishing agent that focuses on Professional Wetcleaning. TrackMoist is a dirt surface performance enhancer. The electronic technology division, GestureTek Media, focuses on touchless human gesture control of digital display screens and human interaction with visual images that are projected onto surfaces of any kind.
Time for a strong rebound:
WNBD: 0.0003 + 500%
Volume: more than 250.000.000
https://twitter.com/WinningCEO
Winning Brands Corporation is a Canada-based company. The Company is providing products in two categories: chemical and electronic technology. The chemical division, Niagara Mist Marketing, focuses on cleaning agents with an environmental focus. Its product portfolio includes 1000+ stain remover, BRILLIANT Professional Laundry Solutions, TrackMoist, and ReGUARD4. 1000+ Stain Remover is a solution that spans a range of clean-up situations from home improvement messes to degreasing and stain removal of all sorts from both hard surfaces (floors, walls, decks) and soft surfaces (carpets and fabric). BRILLIANT Professional Laundry Solutions is a commercial garment cleaning and finishing agent that focuses on Professional Wetcleaning. TrackMoist is a dirt surface performance enhancer. The electronic technology division, GestureTek Media, focuses on touchless human gesture control of digital display screens and human interaction with visual images that are projected onto surfaces of any kind.
All time low
RCON: 0.1201 – 11.69%
Volume 7.265.227
Shares Outstanding 141.7M
Mr. Shenping Yin, Founder and CEO of Recon said, "Fiscal year ended 2023 was a year of change, challenge and opportunity for Recon. As a result of the impact of the outbreak and changes in the industry, our established business volume temporarily declined and recovered less than optimally, and resulting in a decline in overall revenue in fiscal year ended 2023, but our gross margins improved due to management efficiencies and the overall recovery of the industry.
We believe that China's investment and demand in the oil industry will not decrease in the near future, and we believe that there are still many opportunities for growth in the oil industry. Recon will continue to benefit from this trend. We expect a significant increase in the volume of business in the oilfield services segment in the coming year. We are also expanding our business focus from oilfield service segment to broader energy sectors, including carbon-zero opportunities and alternative materials for primary petroleum products. We are actively exploring the chemical recycling business of low-value plastics based on waste treatment and recycling, and have reached preliminary cooperation agreements and market expansion and sales intentions with key upstream and downstream customers. Our drive has always been to maximize the long-term benefits for our company and our shareholders based on our experience and resources in the petrochemical and energy industries."
Fiscal Year Ended 2023 Financial Results:
Revenue
Total revenues for the year ended June 30, 2023 were approximately RMB67.1 million ($9.3 million), a decrease of approximately RMB16.7 million ($2.3 million) or 19.9% from RMB83.8million ($12.5 million) for the same period in 2022. The overall decrease in revenue was mainly due to decrease from all four segments during the year ended June 30, 2023.
- Revenue from automation product and software decreased by RMB5.3 million ($0.7 million) or 316.6%. The decrease was mainly caused by decreased orders from JiDong oilfield as this client reduced their investment budget and oil and gas extraction activities.
- Revenue from equipment and accessories decreased by ¥0.9 million ($0.1 million) or 5.3% as we decided not to continue working with some oilfield client with low production levels and allocated our sales and service resources into some larger oilfield companies. We believe this was a temporary decline. Our revenue from this segment will increase in the coming year.
- Revenue from oilfield environmental protection decreased by RMB6.2million ($0.9 million) or 24.5%. This was mainly caused by less raw materials we could collect. As a result, our revenue decreased due to lower processing volume compared to the same period last year.
- Revenue from platform outsourcing services decreased by RMB4.2 million ($0.6 million) or 45.2%. The decrease was mainly due to less overall economic activities and lower refueling volumes at gas stations, and change in the method of settlement with major customers, from the original service fee based on a percentage of the volume and transaction amount to a basic fixed monthly service fee.
Cost of revenue
Cost of revenues decreased from RMB64.4 million ($9.6 million) for the year ended June 30, 2022 to RMB48.2 million ($6.7 million) for the same period in 2023. This decrease was mainly caused by the decreased cost of revenue from automation product and software, oilfield environmental protection and platform outsourcing services segments, which was partially offset by the decreased cost of revenue from equipment and accessories segment during the year ended June 30, 2023.
Gross profit
Gross profit decreased to RMB18.9 million ($2.6 million) for the year ended June 30, 2023 from RMB19.4 million ($2.9 million) for the same period in 2022. Gross profit as a percentage of revenue increased to 28.1% for the year ended June 30, 2023 from 23.2% for the same period in 2022.
- For the years ended June 30, 2022 and 2023, our gross profit from automation product and software was approximately RMB2.1 million and RMB3.0 million ($0.4 million), respectively, representing an increase in gross profit of approximately RMB0.9 million ($0.1 million) or 42.4%. In year 2021, we mainly carried out contracts that were signed during the COVID-19 and low oil price period, during which we used a low-margin strategy to maintain our cooperation business with clients. As oil price increase in 2022, our customers recovered and contract terms were improved and our margin increased and the margin percentage will also be higher.
- For the years ended June 30, 2022 and 2023, gross profit from equipment and accessories was approximately RMB6.7 million and RMB7.3 million ($1.0 million), respectively, representing a slight increase of approximately RMB0.6 million ($0.09 million) or 9.3%. This was mainly driven by high oil price and more demands for heating furnaces with higher margin rather than accessories with lower margin.
- For the years ended June 30, 2022 and 2023, gross profit from oilfield environmental protection was approximately RMB5.1 million and RMB5.2 million ($0.7 million), respectively, maintaining at a stable level.
- For the years ended June 30, 2022 and 2023, gross profit from platform outsourcing services was approximately RMB5.5 million and RMB3.4 million ($0.5 million), respectively, representing a decrease of approximately RMB2.1 million ($0.3 million) or 38.6%, this was mainly because personnel expenses, which constitutes major part of our costs, reduced during the year ended June 30, 2023.
Operating expenses
Selling expenses increased by 4.8%, or RMB0.4 million ($0.07 million), from RMB10.2 million in the year ended June 30, 2022 to RMB10.6 million ($1.5 million) in the same period of 2023.
General and administrative expenses decreased by 7.8%, or RMB6.5 million ($0.9 million), from RMB83.3 million in the year ended June 30, 2022 to RMB76.8 million ($10.6 million) in the same period of 2023.
Net recovery of credit losses of RMB0.7 million for the year ended June 30, 2022 as compared to net recovery of credit losses of RMB9.0 million ($1.2 million) for the same period in 2023.
Research and development expenses remained relatively stable with a slight decrease by 1.8%, or RMB0.2 million ($0.02 million) from RMB9.0 million for the year ended June 30, 2022 to RMB8.8 million ($1.2 million) for the same period of 2023.
Loss from operations
Loss from operations was RMB69.3 million ($9.6 million) for the year ended June 30, 2023, compared to a loss of RMB82.3 million for the same period of 2022. This RMB13.0 million ($1.8 million) decrease in loss from operations was primarily due to the decrease in operating expense as discussed above.
Gain in fair value changes of warrant liability
The Company classified the warrants issued in connection with common share offering as liabilities at their fair value and adjusted the warrant instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. Gain in change in fair value of warrant liability was RMB174.5 million and RMB6.1 million ($0.8 million) for the years ended June 30, 2022 and 2023, respectively.
Impairment loss on goodwill and intangible assets
In conjunction with the preparation of our consolidated financial statement for years ended June 30, 2022 and 2023, the management performed evaluation on the impairment of goodwill and intangible assets and recorded an impairment loss on goodwill and intangible assets of RMB2.3 million and RMB10.0 million ($1.4 million) for the years ended June 30, 2022 and 2023, respectively. The impairment was mainly due to the decision of the major customers to develop their own autonomous unified system and to significantly reduce the procurement of third-party services. This change has had a significant and negative impact on FGS's business model and enterprise value.
Interest income
Net interest income was RMB11.1 million ($1.5 million) for the year ended June 30, 2023, compared to net interest income of RMB3.8 million for the same period of 2022. The RMB.3 million ($1.0 million) increase in net interest income was primarily due to the increased interest-bearing loans to third parties and increased short-term investments we invested during the year ended June 30, 2023.
Other income (expenses), net.
Other net income was RMB0.7 million ($0.1 million) for the year ended June 30, 2023, compared to other net expenses of RMB0.1 million for the same period of 2022.
Net income (loss)
As a result of the factors described above, net loss was RMB61.5 million ($8.5 million) for the year ended June 30, 2023, an increase of RMB155.8 million ($21.5 million) from net income of RMB94.3 million for the same period of 2022.
Cash and short-term investment
As of June 30, 2023, we had cash in the amount of approximately RMB104.1 million ($14.4 million) and short-term investment in bank fixed income product of approximately RMB184.2 million ($25.4 million). As of June 30, 2022, we had cash in the amount of approximately RMB317.0 million ($47.3 million).
Recon Technology, Ltd. provides hardware, software, and on-site services to companies in the petroleum mining and extraction industry in the People's Republic of China. The company offers equipment, tools, and other components and parts related to oilfield production and other energy industries; and develops and sells industrial automation control and information solutions. It also provides equipment for oil and gas production and transportation, including heating furnaces and burner, as well as improvement techniques comprising packers of fracturing; production packers; sand prevention in oil and water wells; water locating and plugging techniques; fissure shaper; fracture acidizing techniques; and electronic broken-down services to resolve block-up and freezing problems. In addition, the company offers automation systems and services, including pumping unit controller that monitors the pumping units and collects data; RTU to monitor natural gas wells and collect gas well pressure data; wireless dynamometers and wireless pressure gauges; electric multi-way valves for oilfield metering station flow control; and natural gas flow computer systems. Further, it provides Recon SCADA oilfield monitor and data acquisition system for supervision and data collection; EPC service of pipeline SCADA system for pipeline monitoring and data acquisition; EPC service of oil and gas wells SCADA system for monitoring and data acquisition of oil wells and natural gas wells; EPC service of oilfield video surveillance and control system to control the oil and gas wellhead and measurement station areas; and technique service for digital oilfield transformation. Additionally, the company offers oilfield waste water treatment solutions and related chemicals; oily sludge disposal solutions; and gas station operation and management solution. Recon Technology, Ltd. was incorporated in 2007 and is headquartered in Beijing, the People's Republic of China.
All time low
RCON: 0.1201 – 11.69%
Volume 7.265.227
Shares Outstanding 141.7M
Mr. Shenping Yin, Founder and CEO of Recon said, "Fiscal year ended 2023 was a year of change, challenge and opportunity for Recon. As a result of the impact of the outbreak and changes in the industry, our established business volume temporarily declined and recovered less than optimally, and resulting in a decline in overall revenue in fiscal year ended 2023, but our gross margins improved due to management efficiencies and the overall recovery of the industry.
We believe that China's investment and demand in the oil industry will not decrease in the near future, and we believe that there are still many opportunities for growth in the oil industry. Recon will continue to benefit from this trend. We expect a significant increase in the volume of business in the oilfield services segment in the coming year. We are also expanding our business focus from oilfield service segment to broader energy sectors, including carbon-zero opportunities and alternative materials for primary petroleum products. We are actively exploring the chemical recycling business of low-value plastics based on waste treatment and recycling, and have reached preliminary cooperation agreements and market expansion and sales intentions with key upstream and downstream customers. Our drive has always been to maximize the long-term benefits for our company and our shareholders based on our experience and resources in the petrochemical and energy industries."
Fiscal Year Ended 2023 Financial Results:
Revenue
Total revenues for the year ended June 30, 2023 were approximately RMB67.1 million ($9.3 million), a decrease of approximately RMB16.7 million ($2.3 million) or 19.9% from RMB83.8million ($12.5 million) for the same period in 2022. The overall decrease in revenue was mainly due to decrease from all four segments during the year ended June 30, 2023.
- Revenue from automation product and software decreased by RMB5.3 million ($0.7 million) or 316.6%. The decrease was mainly caused by decreased orders from JiDong oilfield as this client reduced their investment budget and oil and gas extraction activities.
- Revenue from equipment and accessories decreased by ¥0.9 million ($0.1 million) or 5.3% as we decided not to continue working with some oilfield client with low production levels and allocated our sales and service resources into some larger oilfield companies. We believe this was a temporary decline. Our revenue from this segment will increase in the coming year.
- Revenue from oilfield environmental protection decreased by RMB6.2million ($0.9 million) or 24.5%. This was mainly caused by less raw materials we could collect. As a result, our revenue decreased due to lower processing volume compared to the same period last year.
- Revenue from platform outsourcing services decreased by RMB4.2 million ($0.6 million) or 45.2%. The decrease was mainly due to less overall economic activities and lower refueling volumes at gas stations, and change in the method of settlement with major customers, from the original service fee based on a percentage of the volume and transaction amount to a basic fixed monthly service fee.
Cost of revenue
Cost of revenues decreased from RMB64.4 million ($9.6 million) for the year ended June 30, 2022 to RMB48.2 million ($6.7 million) for the same period in 2023. This decrease was mainly caused by the decreased cost of revenue from automation product and software, oilfield environmental protection and platform outsourcing services segments, which was partially offset by the decreased cost of revenue from equipment and accessories segment during the year ended June 30, 2023.
Gross profit
Gross profit decreased to RMB18.9 million ($2.6 million) for the year ended June 30, 2023 from RMB19.4 million ($2.9 million) for the same period in 2022. Gross profit as a percentage of revenue increased to 28.1% for the year ended June 30, 2023 from 23.2% for the same period in 2022.
- For the years ended June 30, 2022 and 2023, our gross profit from automation product and software was approximately RMB2.1 million and RMB3.0 million ($0.4 million), respectively, representing an increase in gross profit of approximately RMB0.9 million ($0.1 million) or 42.4%. In year 2021, we mainly carried out contracts that were signed during the COVID-19 and low oil price period, during which we used a low-margin strategy to maintain our cooperation business with clients. As oil price increase in 2022, our customers recovered and contract terms were improved and our margin increased and the margin percentage will also be higher.
- For the years ended June 30, 2022 and 2023, gross profit from equipment and accessories was approximately RMB6.7 million and RMB7.3 million ($1.0 million), respectively, representing a slight increase of approximately RMB0.6 million ($0.09 million) or 9.3%. This was mainly driven by high oil price and more demands for heating furnaces with higher margin rather than accessories with lower margin.
- For the years ended June 30, 2022 and 2023, gross profit from oilfield environmental protection was approximately RMB5.1 million and RMB5.2 million ($0.7 million), respectively, maintaining at a stable level.
- For the years ended June 30, 2022 and 2023, gross profit from platform outsourcing services was approximately RMB5.5 million and RMB3.4 million ($0.5 million), respectively, representing a decrease of approximately RMB2.1 million ($0.3 million) or 38.6%, this was mainly because personnel expenses, which constitutes major part of our costs, reduced during the year ended June 30, 2023.
Operating expenses
Selling expenses increased by 4.8%, or RMB0.4 million ($0.07 million), from RMB10.2 million in the year ended June 30, 2022 to RMB10.6 million ($1.5 million) in the same period of 2023.
General and administrative expenses decreased by 7.8%, or RMB6.5 million ($0.9 million), from RMB83.3 million in the year ended June 30, 2022 to RMB76.8 million ($10.6 million) in the same period of 2023.
Net recovery of credit losses of RMB0.7 million for the year ended June 30, 2022 as compared to net recovery of credit losses of RMB9.0 million ($1.2 million) for the same period in 2023.
Research and development expenses remained relatively stable with a slight decrease by 1.8%, or RMB0.2 million ($0.02 million) from RMB9.0 million for the year ended June 30, 2022 to RMB8.8 million ($1.2 million) for the same period of 2023.
Loss from operations
Loss from operations was RMB69.3 million ($9.6 million) for the year ended June 30, 2023, compared to a loss of RMB82.3 million for the same period of 2022. This RMB13.0 million ($1.8 million) decrease in loss from operations was primarily due to the decrease in operating expense as discussed above.
Gain in fair value changes of warrant liability
The Company classified the warrants issued in connection with common share offering as liabilities at their fair value and adjusted the warrant instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. Gain in change in fair value of warrant liability was RMB174.5 million and RMB6.1 million ($0.8 million) for the years ended June 30, 2022 and 2023, respectively.
Impairment loss on goodwill and intangible assets
In conjunction with the preparation of our consolidated financial statement for years ended June 30, 2022 and 2023, the management performed evaluation on the impairment of goodwill and intangible assets and recorded an impairment loss on goodwill and intangible assets of RMB2.3 million and RMB10.0 million ($1.4 million) for the years ended June 30, 2022 and 2023, respectively. The impairment was mainly due to the decision of the major customers to develop their own autonomous unified system and to significantly reduce the procurement of third-party services. This change has had a significant and negative impact on FGS's business model and enterprise value.
Interest income
Net interest income was RMB11.1 million ($1.5 million) for the year ended June 30, 2023, compared to net interest income of RMB3.8 million for the same period of 2022. The RMB.3 million ($1.0 million) increase in net interest income was primarily due to the increased interest-bearing loans to third parties and increased short-term investments we invested during the year ended June 30, 2023.
Other income (expenses), net.
Other net income was RMB0.7 million ($0.1 million) for the year ended June 30, 2023, compared to other net expenses of RMB0.1 million for the same period of 2022.
Net income (loss)
As a result of the factors described above, net loss was RMB61.5 million ($8.5 million) for the year ended June 30, 2023, an increase of RMB155.8 million ($21.5 million) from net income of RMB94.3 million for the same period of 2022.
Cash and short-term investment
As of June 30, 2023, we had cash in the amount of approximately RMB104.1 million ($14.4 million) and short-term investment in bank fixed income product of approximately RMB184.2 million ($25.4 million). As of June 30, 2022, we had cash in the amount of approximately RMB317.0 million ($47.3 million).
Recon Technology, Ltd. provides hardware, software, and on-site services to companies in the petroleum mining and extraction industry in the People's Republic of China. The company offers equipment, tools, and other components and parts related to oilfield production and other energy industries; and develops and sells industrial automation control and information solutions. It also provides equipment for oil and gas production and transportation, including heating furnaces and burner, as well as improvement techniques comprising packers of fracturing; production packers; sand prevention in oil and water wells; water locating and plugging techniques; fissure shaper; fracture acidizing techniques; and electronic broken-down services to resolve block-up and freezing problems. In addition, the company offers automation systems and services, including pumping unit controller that monitors the pumping units and collects data; RTU to monitor natural gas wells and collect gas well pressure data; wireless dynamometers and wireless pressure gauges; electric multi-way valves for oilfield metering station flow control; and natural gas flow computer systems. Further, it provides Recon SCADA oilfield monitor and data acquisition system for supervision and data collection; EPC service of pipeline SCADA system for pipeline monitoring and data acquisition; EPC service of oil and gas wells SCADA system for monitoring and data acquisition of oil wells and natural gas wells; EPC service of oilfield video surveillance and control system to control the oil and gas wellhead and measurement station areas; and technique service for digital oilfield transformation. Additionally, the company offers oilfield waste water treatment solutions and related chemicals; oily sludge disposal solutions; and gas station operation and management solution. Recon Technology, Ltd. was incorporated in 2007 and is headquartered in Beijing, the People's Republic of China.
GDHG: down 99% because of fake news!!
The true story: https://www.youtube.com/embed/AXkmlKj9keA
Time for a strong recovery:
Apr 8, 2024 0.3300 0.3660 0.2310 0.2400 0.2400 10,559,000
Apr 1, 2024 0.4850 0.4850 0.3200 0.3300 0.3300 8,721,200
Mar 25, 2024 0.5000 0.5400 0.4400 0.4630 0.4630 9,059,800
Mar 18, 2024 0.4660 0.5200 0.4500 0.4820 0.4820 6,518,900
Mar 11, 2024 0.4970 0.5200 0.4390 0.4400 0.4400 8,524,800
Mar 4, 2024 0.4800 0.5500 0.4500 0.4970 0.4970 14,195,600
Feb 26, 2024 0.4960 0.6200 0.4410 0.4880 0.4880 25,947,800
Feb 19, 2024 0.4900 0.5670 0.4100 0.4730 0.4730 18,509,200
Feb 12, 2024 0.5700 0.6100 0.4500 0.5040 0.5040 19,012,600
Feb 5, 2024 0.6100 0.7690 0.4850 0.5700 0.5700 6,939,200
Jan 29, 2024 0.5750 0.8470 0.5400 0.6060 0.6060 5,034,100
Jan 22, 2024 0.4600 0.5600 0.4410 0.5440 0.5440 1,475,100
Jan 15, 2024 0.5510 0.5600 0.4400 0.4510 0.4510 1,080,700
Jan 8, 2024 0.6060 0.6200 0.5390 0.5600 0.5600 2,384,400
Jan 1, 2024 0.7450 0.7450 0.6130 0.6240 0.6240 2,211,100
Dec 25, 2023 1.0900 1.1200 0.7020 0.7300 0.7300 6,992,700
Dec 18, 2023 1.2400 1.4900 1.0700 1.1400 1.1400 6,038,400
Dec 11, 2023 1.1700 1.5500 1.0500 1.2900 1.2900 9,870,200
Dec 4, 2023 19.5300 22.3000 1.3300 1.3600 1.3600 17,464,600
Nov 27, 2023 22.5200 24.8300 19.7500 20.5500 20.5500 1,834,400
Nov 20, 2023 21.8200 24.3000 19.7500 23.4900 23.4900 1,428,500
Nov 13, 2023 23.0000 24.9900 11.0050 20.3900 20.3900 2,547,300
GDHG: down 99% because of fake news!!
The true story: https://www.youtube.com/embed/AXkmlKj9keA
Time for a strong recovery:
Apr 8, 2024 0.3300 0.3660 0.2310 0.2400 0.2400 10,559,000
Apr 1, 2024 0.4850 0.4850 0.3200 0.3300 0.3300 8,721,200
Mar 25, 2024 0.5000 0.5400 0.4400 0.4630 0.4630 9,059,800
Mar 18, 2024 0.4660 0.5200 0.4500 0.4820 0.4820 6,518,900
Mar 11, 2024 0.4970 0.5200 0.4390 0.4400 0.4400 8,524,800
Mar 4, 2024 0.4800 0.5500 0.4500 0.4970 0.4970 14,195,600
Feb 26, 2024 0.4960 0.6200 0.4410 0.4880 0.4880 25,947,800
Feb 19, 2024 0.4900 0.5670 0.4100 0.4730 0.4730 18,509,200
Feb 12, 2024 0.5700 0.6100 0.4500 0.5040 0.5040 19,012,600
Feb 5, 2024 0.6100 0.7690 0.4850 0.5700 0.5700 6,939,200
Jan 29, 2024 0.5750 0.8470 0.5400 0.6060 0.6060 5,034,100
Jan 22, 2024 0.4600 0.5600 0.4410 0.5440 0.5440 1,475,100
Jan 15, 2024 0.5510 0.5600 0.4400 0.4510 0.4510 1,080,700
Jan 8, 2024 0.6060 0.6200 0.5390 0.5600 0.5600 2,384,400
Jan 1, 2024 0.7450 0.7450 0.6130 0.6240 0.6240 2,211,100
Dec 25, 2023 1.0900 1.1200 0.7020 0.7300 0.7300 6,992,700
Dec 18, 2023 1.2400 1.4900 1.0700 1.1400 1.1400 6,038,400
Dec 11, 2023 1.1700 1.5500 1.0500 1.2900 1.2900 9,870,200
Dec 4, 2023 19.5300 22.3000 1.3300 1.3600 1.3600 17,464,600
Nov 27, 2023 22.5200 24.8300 19.7500 20.5500 20.5500 1,834,400
Nov 20, 2023 21.8200 24.3000 19.7500 23.4900 23.4900 1,428,500
Nov 13, 2023 23.0000 24.9900 11.0050 20.3900 20.3900 2,547,300